1
|
Righini C, Bolla M, Colonna M. Thoughts about the evolution of cancer registries in France. Eur Ann Otorhinolaryngol Head Neck Dis 2024; 141:59-60. [PMID: 37393191 DOI: 10.1016/j.anorl.2023.06.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/03/2023]
Affiliation(s)
- C Righini
- Service hospitalo-universitaire de chirurgie cervico-faciale du centre hospitalier universitaire de Grenoble (CHUGA), Grenoble, France; Université Grenoble-Alpes (UGA), Grenoble, France.
| | - M Bolla
- Oncology-Radiotherapy, université Grenoble-Alpes (UGA), Grenoble, France
| | - M Colonna
- Isère Departmental Cancer Registry, centre hospitalier universitaire de Grenoble-Alpes (CHUGA), Grenoble, France
| |
Collapse
|
2
|
Nanni A, Colonna M, Liberati G, Bonoli A. A novel process for the complete recycling of exhausted coffee capsules with a fully circular approach: Design of the industrial plant and Techno-Economic analysis of the process. Waste Manag 2024; 174:114-125. [PMID: 38041980 DOI: 10.1016/j.wasman.2023.11.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/22/2023] [Revised: 11/07/2023] [Accepted: 11/23/2023] [Indexed: 12/04/2023]
Abstract
The objective of this paper is to present the technical and feasibility analysis of an innovative mechanical recycling system for exhausted coffee capsules. This recycling process involved the sorting of spent coffee grounds (SGC) and the subsequent drying and melt-mixing of a portion of these grounds with the remaining capsule components, mainly composed of polypropylene (PP), along with optional virgin PP. These newly developed composite materials exhibited mechanical and rheological properties comparable or even surpassing those of virgin PP. They were also successfully utilized for the injection of new capsule shells, thus alignin with the principles of the circular economy. In addition to the technical aspects, this paper present a comprehensive Techno-Economic Analysis (TEA) of the proposed recycling processes, considering the inclusion of virgin PP (0-20 %) and the initial moisture content (MSGC) of SGC(5-55 %) as varying factors. An industrial plant, designed to handle up to 190 million exhausted coffee capsules and produce up to 1500 tons of recycled compund was appropriately sized. The analysis revealed that processes are profitable across all examined scenarios and that the Net Present Value ranged between 800 k€ (for vPP = 20 % and MSGC = 55 %) and 2000 k€ (for vPP = 0 % and MSGC = 5 %).
Collapse
Affiliation(s)
- A Nanni
- SPORT TECHNOLOGY LAB - DICAM, University of Bologna, Via Terracini 28, 40131 Bologna, Italy; RE-SPORT srl, via G. Fanin 48, 40127 Bologna, Italy; AgroMateriae srl, Via Granarolo 177/3, 48018 Faenza RA, Italy.
| | - M Colonna
- SPORT TECHNOLOGY LAB - DICAM, University of Bologna, Via Terracini 28, 40131 Bologna, Italy; RE-SPORT srl, via G. Fanin 48, 40127 Bologna, Italy
| | - G Liberati
- Raw Materials Engineering and Circular Economy LAB - DICAM, University of Bologna, Via Terracini 28, 40131, Bologna, Italy
| | - A Bonoli
- Raw Materials Engineering and Circular Economy LAB - DICAM, University of Bologna, Via Terracini 28, 40131, Bologna, Italy
| |
Collapse
|
3
|
Rivas M, Pichel M, Colonna M, Casanello AL, Alconcher LF, Galavotti J, Principi I, Araujo SP, Ramírez FB, González G, Pianciola LA, Mazzeo M, Suarez Á, Oderiz S, Ghezzi LFR, Arrigo DJ, Paladini JH, Baroni MR, Pérez S, Tamborini A, Chinen I, Miliwebsky ES, Goldbaum F, Muñoz L, Spatz L, Sanguineti S. Surveillance of Shiga toxin-producing Escherichia coli associated bloody diarrhea in Argentina. Rev Argent Microbiol 2023; 55:345-354. [PMID: 37301652 DOI: 10.1016/j.ram.2023.03.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2022] [Revised: 12/12/2022] [Accepted: 03/27/2023] [Indexed: 06/12/2023] Open
Abstract
In Argentina, hemolytic uremic syndrome (HUS) caused by Shiga toxin-producing Escherichia coli (STEC-HUS) infection is endemic, and reliable data about prevalence and risk factors have been available since 2000. However, information about STEC-associated bloody diarrhea (BD) is limited. A prospective study was performed during the period October 2018-June 2019 in seven tertiary-hospitals and 18 referral units from different regions, aiming to determine (i) the frequency of STEC-positive BD cases in 714 children aged 1-9 years of age and (ii) the rate of progression of bloody diarrhea to HUS. The number and regional distribution of STEC-HUS cases in the same hospitals and during the same period were also assessed. Twenty-nine (4.1%) of the BD patients were STEC-positive, as determined by the Shiga Toxin Quik Chek (STQC) test and/or the multiplex polymerase chain reaction (mPCR) assay. The highest frequencies were found in the Southern region (Neuquén, 8.7%; Bahía Blanca, 7.9%), in children between 12 and 23 month of age (8.8%), during summertime. Four (13.8%) cases progressed to HUS, three to nine days after diarrhea onset. Twenty-seven STEC-HUS in children under 5 years of age (77.8%) were enrolled, 51.9% were female; 44% were Stx-positive by STQC and all by mPCR. The most common serotypes were O157:H7 and O145:H28 and the prevalent genotypes, both among BD and HUS cases, were stx2a-only or -associated. Considering the endemic behavior of HUS and its high incidence, these data show that the rate of STEC-positive cases is low among BD patients. However, the early recognition of STEC-positive cases is important for patient monitoring and initiation of supportive treatment.
Collapse
Affiliation(s)
- Marta Rivas
- Inmunova S.A., Av. 25 de Mayo 1021, San Martín, 1650 Buenos Aires, Argentina.
| | - Mariana Pichel
- Inmunova S.A., Av. 25 de Mayo 1021, San Martín, 1650 Buenos Aires, Argentina
| | - Mariana Colonna
- Inmunova S.A., Av. 25 de Mayo 1021, San Martín, 1650 Buenos Aires, Argentina
| | | | - Laura F Alconcher
- Hospital Interzonal "Dr. José Penna", Av. Laínez 2401, B8000 Bahía Blanca, Buenos Aires, Argentina
| | - Jimena Galavotti
- Hospital Interzonal "Dr. José Penna", Av. Laínez 2401, B8000 Bahía Blanca, Buenos Aires, Argentina
| | - Iliana Principi
- Hospital de Niños "Dr. Humberto Notti", Av. Bandera de los Andes 2603, M5521 Guaymallén, Mendoza, Argentina
| | - Sofía Pérez Araujo
- Hospital de Niños "Dr. Humberto Notti", Av. Bandera de los Andes 2603, M5521 Guaymallén, Mendoza, Argentina
| | - Flavia B Ramírez
- Hospital Provincial Neuquén Dr. Castro Rendón, Buenos Aires 450, Q8300 Neuquén, Argentina
| | - Gladys González
- Hospital Provincial Neuquén Dr. Castro Rendón, Buenos Aires 450, Q8300 Neuquén, Argentina
| | - Luis A Pianciola
- Laboratorio Central, Gregorio Martínez 65, Q8300 Neuquén, Argentina
| | - Melina Mazzeo
- Laboratorio Central, Gregorio Martínez 65, Q8300 Neuquén, Argentina
| | - Ángela Suarez
- Hospital De Niños "Sor María Ludovica", Calle 14 1631 entre 65 y 66, B1904CSI La Plata, Buenos Aires, Argentina
| | - Sebastián Oderiz
- Hospital De Niños "Sor María Ludovica", Calle 14 1631 entre 65 y 66, B1904CSI La Plata, Buenos Aires, Argentina
| | - Lidia F R Ghezzi
- Hospital Italiano de Buenos Aires, Tte. Gral. Juan Domingo Perón 4190, C1199AB, Buenos Aires, Argentina
| | - Diego J Arrigo
- Hospital Italiano de Buenos Aires, Tte. Gral. Juan Domingo Perón 4190, C1199AB, Buenos Aires, Argentina
| | - José H Paladini
- Hospital Dr. Orlando Alassia, Mendoza 4151, 3000 Santa Fe, Argentina
| | - María R Baroni
- Hospital Dr. Orlando Alassia, Mendoza 4151, 3000 Santa Fe, Argentina
| | - Susana Pérez
- Hospital "Dr. Lucio Molas", Raúl B. Díaz Pilcomayo, 6300 Santa Rosa, La Pampa, Argentina
| | - Ana Tamborini
- Hospital "Dr. Lucio Molas", Raúl B. Díaz Pilcomayo, 6300 Santa Rosa, La Pampa, Argentina
| | - Isabel Chinen
- Servicio Fisiopatogenia, Instituto Nacional de Enfermedades Infecciosas, ANLIS "Dr. Carlos G. Malbrán", Av. Vélez Sarsfield 563, 1281 Buenos Aires, Argentina
| | - Elizabeth S Miliwebsky
- Servicio Fisiopatogenia, Instituto Nacional de Enfermedades Infecciosas, ANLIS "Dr. Carlos G. Malbrán", Av. Vélez Sarsfield 563, 1281 Buenos Aires, Argentina
| | - Fernando Goldbaum
- Inmunova S.A., Av. 25 de Mayo 1021, San Martín, 1650 Buenos Aires, Argentina
| | - Luciana Muñoz
- Inmunova S.A., Av. 25 de Mayo 1021, San Martín, 1650 Buenos Aires, Argentina
| | - Linus Spatz
- Inmunova S.A., Av. 25 de Mayo 1021, San Martín, 1650 Buenos Aires, Argentina
| | - Santiago Sanguineti
- Inmunova S.A., Av. 25 de Mayo 1021, San Martín, 1650 Buenos Aires, Argentina
| |
Collapse
|
4
|
Girardi F, Matz M, Stiller C, You H, Marcos Gragera R, Valkov MY, Bulliard JL, De P, Morrison D, Wanner M, O'Brian DK, Saint-Jacques N, Coleman MP, Allemani C, Hamdi-Chérif M, Kara L, Meguenni K, Regagba D, Bayo S, Cheick Bougadari T, Manraj SS, Bendahhou K, Ladipo A, Ogunbiyi OJ, Somdyala NIM, Chaplin MA, Moreno F, Calabrano GH, Espinola SB, Carballo Quintero B, Fita R, Laspada WD, Ibañez SG, Lima CA, Da Costa AM, De Souza PCF, Chaves J, Laporte CA, Curado MP, de Oliveira JC, Veneziano CLA, Veneziano DB, Almeida ABM, Latorre MRDO, Rebelo MS, Santos MO, Azevedo e Silva G, Galaz JC, Aparicio Aravena M, Sanhueza Monsalve J, Herrmann DA, Vargas S, Herrera VM, Uribe CJ, Bravo LE, Garcia LS, Arias-Ortiz NE, Morantes D, Jurado DM, Yépez Chamorro MC, Delgado S, Ramirez M, Galán Alvarez YH, Torres P, Martínez-Reyes F, Jaramillo L, Quinto R, Castillo J, Mendoza M, Cueva P, Yépez JG, Bhakkan B, Deloumeaux J, Joachim C, Macni J, Carrillo R, Shalkow Klincovstein J, Rivera Gomez R, Perez P, Poquioma E, Tortolero-Luna G, Zavala D, Alonso R, Barrios E, Eckstrand A, Nikiforuk C, Woods RR, Noonan G, Turner D, Kumar E, Zhang B, Dowden JJ, Doyle GP, Saint-Jacques N, Walsh G, Anam A, De P, McClure CA, Vriends KA, Bertrand C, Ramanakumar AV, Davis L, Kozie S, Freeman T, George JT, Avila RM, O’Brien DK, Holt A, Almon L, Kwong S, Morris C, Rycroft R, Mueller L, Phillips CE, Brown H, Cromartie B, Ruterbusch J, Schwartz AG, Levin GM, Wohler B, Bayakly R, Ward KC, Gomez SL, McKinley M, Cress R, Davis J, Hernandez B, Johnson CJ, Morawski BM, Ruppert LP, Bentler S, Charlton ME, Huang B, Tucker TC, Deapen D, Liu L, Hsieh MC, Wu XC, Schwenn M, Stern K, Gershman ST, Knowlton RC, Alverson G, Weaver T, Desai J, Rogers DB, Jackson-Thompson J, Lemons D, Zimmerman HJ, Hood M, Roberts-Johnson J, Hammond W, Rees JR, Pawlish KS, Stroup A, Key C, Wiggins C, Kahn AR, Schymura MJ, Radhakrishnan S, Rao C, Giljahn LK, Slocumb RM, Dabbs C, Espinoza RE, Aird KG, Beran T, Rubertone JJ, Slack SJ, Oh J, Janes TA, Schwartz SM, Chiodini SC, Hurley DM, Whiteside MA, Rai S, Williams MA, Herget K, Sweeney C, Kachajian J, Keitheri Cheteri MB, Migliore Santiago P, Blankenship SE, Conaway JL, Borchers R, Malicki R, Espinoza J, Grandpre J, Weir HK, Wilson R, Edwards BK, Mariotto A, Rodriguez-Galindo C, Wang N, Yang L, Chen JS, Zhou Y, He YT, Song GH, Gu XP, Mei D, Mu HJ, Ge HM, Wu TH, Li YY, Zhao DL, Jin F, Zhang JH, Zhu FD, Junhua Q, Yang YL, Jiang CX, Biao W, Wang J, Li QL, Yi H, Zhou X, Dong J, Li W, Fu FX, Liu SZ, Chen JG, Zhu J, Li YH, Lu YQ, Fan M, Huang SQ, Guo GP, Zhaolai H, Wei K, Chen WQ, Wei W, Zeng H, Demetriou AV, Mang WK, Ngan KC, Kataki AC, Krishnatreya M, Jayalekshmi PA, Sebastian P, George PS, Mathew A, Nandakumar A, Malekzadeh R, Roshandel G, Keinan-Boker L, Silverman BG, Ito H, Koyanagi Y, Sato M, Tobori F, Nakata I, Teramoto N, Hattori M, Kaizaki Y, Moki F, Sugiyama H, Utada M, Nishimura M, Yoshida K, Kurosawa K, Nemoto Y, Narimatsu H, Sakaguchi M, Kanemura S, Naito M, Narisawa R, Miyashiro I, Nakata K, Mori D, Yoshitake M, Oki I, Fukushima N, Shibata A, Iwasa K, Ono C, Matsuda T, Nimri O, Jung KW, Won YJ, Alawadhi E, Elbasmi A, Ab Manan A, Adam F, Nansalmaa E, Tudev U, Ochir C, Al Khater AM, El Mistiri MM, Lim GH, Teo YY, Chiang CJ, Lee WC, Buasom R, Sangrajrang S, Suwanrungruang K, Vatanasapt P, Daoprasert K, Pongnikorn D, Leklob A, Sangkitipaiboon S, Geater SL, Sriplung H, Ceylan O, Kög I, Dirican O, Köse T, Gurbuz T, Karaşahin FE, Turhan D, Aktaş U, Halat Y, Eser S, Yakut CI, Altinisik M, Cavusoglu Y, Türkköylü A, Üçüncü N, Hackl M, Zborovskaya AA, Aleinikova OV, Henau K, Van Eycken L, Atanasov TY, Valerianova Z, Šekerija M, Dušek L, Zvolský M, Steinrud Mørch L, Storm H, Wessel Skovlund C, Innos K, Mägi M, Malila N, Seppä K, Jégu J, Velten M, Cornet E, Troussard X, Bouvier AM, Guizard AV, Bouvier V, Launoy G, Dabakuyo Yonli S, Poillot ML, Maynadié M, Mounier M, Vaconnet L, Woronoff AS, Daoulas M, Robaszkiewicz M, Clavel J, Poulalhon C, Desandes E, Lacour B, Baldi I, Amadeo B, Coureau G, Monnereau A, Orazio S, Audoin M, D’Almeida TC, Boyer S, Hammas K, Trétarre B, Colonna M, Delafosse P, Plouvier S, Cowppli-Bony A, Molinié F, Bara S, Ganry O, Lapôtre-Ledoux B, Daubisse-Marliac L, Bossard N, Uhry Z, Estève J, Stabenow R, Wilsdorf-Köhler H, Eberle A, Luttmann S, Löhden I, Nennecke AL, Kieschke J, Sirri E, Justenhoven C, Reinwald F, Holleczek B, Eisemann N, Katalinic A, Asquez RA, Kumar V, Petridou E, Ólafsdóttir EJ, Tryggvadóttir L, Murray DE, Walsh PM, Sundseth H, Harney M, Mazzoleni G, Vittadello F, Coviello E, Cuccaro F, Galasso R, Sampietro G, Giacomin A, Magoni M, Ardizzone A, D’Argenzio A, Di Prima AA, Ippolito A, Lavecchia AM, Sutera Sardo A, Gola G, Ballotari P, Giacomazzi E, Ferretti S, Dal Maso L, Serraino D, Celesia MV, Filiberti RA, Pannozzo F, Melcarne A, Quarta F, Andreano A, Russo AG, Carrozzi G, Cirilli C, Cavalieri d’Oro L, Rognoni M, Fusco M, Vitale MF, Usala M, Cusimano R, Mazzucco W, Michiara M, Sgargi P, Boschetti L, Marguati S, Chiaranda G, Seghini P, Maule MM, Merletti F, Spata E, Tumino R, Mancuso P, Cassetti T, Sassatelli R, Falcini F, Giorgetti S, Caiazzo AL, Cavallo R, Piras D, Bella F, Madeddu A, Fanetti AC, Maspero S, Carone S, Mincuzzi A, Candela G, Scuderi T, Gentilini MA, Rizzello R, Rosso S, Caldarella A, Intrieri T, Bianconi F, Contiero P, Tagliabue G, Rugge M, Zorzi M, Beggiato S, Brustolin A, Gatta G, De Angelis R, Vicentini M, Zanetti R, Stracci F, Maurina A, Oniščuka M, Mousavi M, Steponaviciene L, Vincerževskienė I, Azzopardi MJ, Calleja N, Siesling S, Visser O, Johannesen TB, Larønningen S, Trojanowski M, Macek P, Mierzwa T, Rachtan J, Rosińska A, Kępska K, Kościańska B, Barna K, Sulkowska U, Gebauer T, Łapińska JB, Wójcik-Tomaszewska J, Motnyk M, Patro A, Gos A, Sikorska K, Bielska-Lasota M, Didkowska JA, Wojciechowska U, Forjaz de Lacerda G, Rego RA, Carrito B, Pais A, Bento MJ, Rodrigues J, Lourenço A, Mayer-da-Silva A, Coza D, Todescu AI, Valkov MY, Gusenkova L, Lazarevich O, Prudnikova O, Vjushkov DM, Egorova A, Orlov A, Pikalova LV, Zhuikova LD, Adamcik J, Safaei Diba C, Zadnik V, Žagar T, De-La-Cruz M, Lopez-de-Munain A, Aleman A, Rojas D, Chillarón RJ, Navarro AIM, Marcos-Gragera R, Puigdemont M, Rodríguez-Barranco M, Sánchez Perez MJ, Franch Sureda P, Ramos Montserrat M, Chirlaque López MD, Sánchez Gil A, Ardanaz E, Guevara M, Cañete-Nieto A, Peris-Bonet R, Carulla M, Galceran J, Almela F, Sabater C, Khan S, Pettersson D, Dickman P, Staehelin K, Struchen B, Egger Hayoz C, Rapiti E, Schaffar R, Went P, Mousavi SM, Bulliard JL, Maspoli-Conconi M, Kuehni CE, Redmond SM, Bordoni A, Ortelli L, Chiolero A, Konzelmann I, Rohrmann S, Wanner M, Broggio J, Rashbass J, Stiller C, Fitzpatrick D, Gavin A, Morrison DS, Thomson CS, Greene G, Huws DW, Grayson M, Rawcliffe H, Allemani C, Coleman MP, Di Carlo V, Girardi F, Matz M, Minicozzi P, Sanz N, Ssenyonga N, James D, Stephens R, Chalker E, Smith M, Gugusheff J, You H, Qin Li S, Dugdale S, Moore J, Philpot S, Pfeiffer R, Thomas H, Silva Ragaini B, Venn AJ, Evans SM, Te Marvelde L, Savietto V, Trevithick R, Aitken J, Currow D, Fowler C, Lewis C. Global survival trends for brain tumors, by histology: analysis of individual records for 556,237 adults diagnosed in 59 countries during 2000-2014 (CONCORD-3). Neuro Oncol 2023; 25:580-592. [PMID: 36355361 PMCID: PMC10013649 DOI: 10.1093/neuonc/noac217] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Survival is a key metric of the effectiveness of a health system in managing cancer. We set out to provide a comprehensive examination of worldwide variation and trends in survival from brain tumors in adults, by histology. METHODS We analyzed individual data for adults (15-99 years) diagnosed with a brain tumor (ICD-O-3 topography code C71) during 2000-2014, regardless of tumor behavior. Data underwent a 3-phase quality control as part of CONCORD-3. We estimated net survival for 11 histology groups, using the unbiased nonparametric Pohar Perme estimator. RESULTS The study included 556,237 adults. In 2010-2014, the global range in age-standardized 5-year net survival for the most common sub-types was broad: in the range 20%-38% for diffuse and anaplastic astrocytoma, from 4% to 17% for glioblastoma, and between 32% and 69% for oligodendroglioma. For patients with glioblastoma, the largest gains in survival occurred between 2000-2004 and 2005-2009. These improvements were more noticeable among adults diagnosed aged 40-70 years than among younger adults. CONCLUSIONS To the best of our knowledge, this study provides the largest account to date of global trends in population-based survival for brain tumors by histology in adults. We have highlighted remarkable gains in 5-year survival from glioblastoma since 2005, providing large-scale empirical evidence on the uptake of chemoradiation at population level. Worldwide, survival improvements have been extensive, but some countries still lag behind. Our findings may help clinicians involved in national and international tumor pathway boards to promote initiatives aimed at more extensive implementation of clinical guidelines.
Collapse
Affiliation(s)
- Fabio Girardi
- Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK.,Cancer Division, University College London Hospitals NHS Foundation Trust, London, UK.,Division of Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
| | - Melissa Matz
- Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK
| | - Charles Stiller
- National Cancer Registration and Analysis Service, Public Health England, London, UK
| | - Hui You
- Cancer Information Analysis Unit, Cancer Institute NSW, St Leonards, New South Wales, Australia
| | - Rafael Marcos Gragera
- Epidemiology Unit and Girona Cancer Registry, Catalan Institute of Oncology, Girona, Spain
| | - Mikhail Y Valkov
- Department of Radiology, Radiotherapy and Oncology, Northern State Medical University, Arkhangelsk, Russia
| | - Jean-Luc Bulliard
- Centre for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.,Neuchâtel and Jura Tumour Registry, Neuchâtel, Switzerland
| | - Prithwish De
- Surveillance and Cancer Registry, and Research Office, Clinical Institutes and Quality Programs, Ontario Health, Toronto, Ontario, Canada
| | - David Morrison
- Scottish Cancer Registry, Public Health Scotland, Edinburgh, UK
| | - Miriam Wanner
- Cancer Registry Zürich, Zug, Schaffhausen and Schwyz, University Hospital Zürich, Zürich, Switzerland
| | - David K O'Brian
- Alaska Cancer Registry, Alaska Department of Health and Social Services, Anchorage, Alaska, USA
| | - Nathalie Saint-Jacques
- Department of Medicine and Community Health and Epidemiology, Centre for Clinical Research, Dalhousie University, Halifax, Nova Scotia, Canada
| | - Michel P Coleman
- Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK.,Cancer Division, University College London Hospitals NHS Foundation Trust, London, UK
| | - Claudia Allemani
- Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Farizano Salazar DH, Achinelli F, Colonna M, Pérez L, Giménez AA, Ojeda MA, Miranda Puente SN, Sánchez Negrette L, Cañete F, Martelotte Ibarra OI, Sanguineti S, Spatz L, Goldbaum FA, Massa C, Rivas M, Pichel M, Hiriart Y, Zylberman V, Gallego S, Konigheim B, Fernández F, Deprati M, Roubicek I, Giunta DH, Nannini E, Lopardo G, Belloso WH. Safety and effectiveness of RBD-specific polyclonal equine F(ab´)2 fragments for the treatment of hospitalized patients with severe Covid-19 disease: A retrospective cohort study. PLoS One 2022; 17:e0274796. [PMID: 36155545 PMCID: PMC9512184 DOI: 10.1371/journal.pone.0274796] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2022] [Accepted: 09/03/2022] [Indexed: 12/15/2022] Open
Abstract
Background
Passive immunotherapy has been evaluated as a therapeutic alternative for patients with COVID-19 disease. Equine polyclonal immunotherapy for COVID-19 (EPIC) showed adequate safety and potential efficacy in a clinical trial setting and obtained emergency use authorization in Argentina. We studied its utility in a real world setting with a larger population.
Methods
We conducted a retrospective cohort study at “Hospital de Campaña Escuela-Hogar" (HCEH) in Corrientes, Argentina, to assess safety and effectiveness of EPIC in hospitalized adults with severe COVID-19 pneumonia. Primary endpoints were 28-days all-cause mortality and safety. Mortality and improvement in modified WHO clinical scale at 14 and 21 days were secondary endpoints. Potential confounder adjustment was made by logistic regression weighted by the inverse of the probability of receiving the treatment (IPTW) and doubly robust approach.
Findings
Subsequent clinical records of 446 non-exposed (Controls) and 395 exposed (EPIC) patients admitted between November 2020 and April 2021 were analyzed. Median age was 58 years and 56.8% were males. Mortality at 28 days was 15.7% (EPIC) vs. 21.5% (Control). After IPTW adjustment the OR was 0.66 (95% CI: 0.46–0.96) P = 0.03. The effect was more evident in the subgroup who received two EPIC doses (complete treatment, n = 379), OR 0.58 (95% CI 0.39 to 0.85) P = 0.005. Overall and serious adverse events were not significantly different between groups.
Conclusions
In this retrospective cohort study, EPIC showed adequate safety and effectiveness in the treatment of hospitalized patients with severe SARS-CoV-2 disease.
Collapse
Affiliation(s)
| | | | | | - Lucía Pérez
- Department of Research, Hospital Italiano de Buenos Aires. Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
| | - Analía A. Giménez
- Hospital de Campaña Escuela Hogar, Corrientes, Corrientes, Argentina
| | | | | | | | - Florencia Cañete
- Hospital de Campaña Escuela Hogar, Corrientes, Corrientes, Argentina
| | | | | | - Linus Spatz
- Inmunova S.A., Gral. San Martín, Buenos Aires, Argentina
| | - Fernando A. Goldbaum
- Inmunova S.A., Gral. San Martín, Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina
- Fundación Instituto Leloir, IIBBA-CONICET. Ciudad Autónoma de Buenos Aires, Argentina
- CRIP—Centro de Rediseño e Ingeniería de Proteínas UNSAM Campus Miguelete, Gral. San Martín, Buenos Aires, Argentina
| | - Carolina Massa
- Inmunova S.A., Gral. San Martín, Buenos Aires, Argentina
| | - Marta Rivas
- Inmunova S.A., Gral. San Martín, Buenos Aires, Argentina
| | - Mariana Pichel
- Inmunova S.A., Gral. San Martín, Buenos Aires, Argentina
| | - Yanina Hiriart
- Inmunova S.A., Gral. San Martín, Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina
| | - Vanesa Zylberman
- Inmunova S.A., Gral. San Martín, Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina
| | - Sandra Gallego
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina
- Instituto de Virología Dr. José María Vanella, Universidad Nacional de Córdoba, Córdoba, Argentina
| | - Brenda Konigheim
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina
- Instituto de Virología Dr. José María Vanella, Universidad Nacional de Córdoba, Córdoba, Argentina
| | | | - Matías Deprati
- Laboratorio Elea Phoenix S.A., Los Polvorines, Buenos Aires, Argentina
| | - Ian Roubicek
- Inmunova S.A., Gral. San Martín, Buenos Aires, Argentina
| | - Diego H. Giunta
- Department of Research, Hospital Italiano de Buenos Aires. Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina
| | - Esteban Nannini
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina
- Departamento de Enfermedades Infecciosas, Sanatorio Británico, Rosario, Santa Fe, Argentina
| | - Gustavo Lopardo
- Hospital Municipal Dr. Bernardo Houssay, Florida, Provincia de Buenos Aires, Argentina
- Fundación del Centro de Estudios Infectológicos (FUNCEI), Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
| | - Waldo H. Belloso
- Department of Research, Hospital Italiano de Buenos Aires. Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
- * E-mail:
| | | |
Collapse
|
6
|
Gozzi E, La Manna AR, Rossi L, Colonna M, Ulgiati MA, Romagnoli L, Busco S, Parrocchia S, Marrone R, Iavarone C, Arcangeli G, Angelini F, De Masi C, Ambrogi C, Travaini S, Calogero A, Centra A, Ricci F. What hides beneath the scar: sexuality and breast cancer what women don't say: A single-center study. Clin Ter 2022; 173:342-346. [PMID: 35857051 DOI: 10.7417/ct.2022.2443] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
BACKGROUND Breast is a symbol of femininity, motherhood and sexuality. Breast cancer (BC) is the leading cause of cancer death in women worldwide and most frequent cancer in Italy: in 2019, 53.500 new cases were diagnosed. BC and its treatment, the disturbances of body image, and mental health problems such as anxiety and depression could influence sexuality. Very often the aspect of sexuality in BC is likely not to be fully investigated: cultural barriers may also contribute to lack of attention to these issues. In Italy, there are very few Breast Units that provide the figure of the sexologist and psycho-oncologist. METHODS We enlisted 141 BC patients (pts), mean age was 54 years afferent to Breast Unit S. Maria Goretti Hospital, Latina, from March 2019 to March 2020. All pts had undergone surgical intervention. Participants were invited to complete a structured questionnaire, which included four close-up questions regarding self-image, sexual activity, sexual satisfaction, analyzing these aspects before and after BC and its treatments. Finally the participants were asked if they needed the sexologist and psycho-oncologist. RESULTS Only 2/141 pts (1.41%) refused to participate in our study. Of 139 participants, 68 (48.92%) had disturbances of body image, 26 (18.7%) had sexuality greatly negatively affected, and 103 (74.1%) every kind of sexual dissatisfaction after BC. 38 pts (27.3%) would require the help of the sexologist. 135 ( 97%) would require the help of the psycho-oncologist. Despite the negative influence in their body-image and sexuality, few pts require the help of the sexologist, but nearly all pts require the help of the psycho-oncologist. CONCLUSION In our study nearly all pts require the help of the psycho-oncologist, but few pts of the sexologist. Further studies will be needed to understand the reasons for this disparity: at the moment we are carrying out another project following this illustration, with the aim of understanding why this disparity.
Collapse
Affiliation(s)
- E Gozzi
- Medical Oncology Unit, Regina Apostolorum Hospital, Albano, Rome, Italy
| | - A R La Manna
- UOC Breast Unit Latina, S. Maria Goretti Hospital, Latina, Italy
| | - L Rossi
- UOC of Oncology - ASL Latina - Distretto 1, University of Rome "Sapienza", Aprilia (LT), Italy
| | - M Colonna
- UOSD of Oncology - A. Fiorini Hospital Terracina, Italy
| | - M A Ulgiati
- UOC Breast Unit Latina, S. Maria Goretti Hospital, Latina, Italy
| | - L Romagnoli
- UOC of Clinical Control And Governance Programming - ASL Latina. Italy
| | - S Busco
- UOC of Clinical Control And Governance Programming - ASL Latina. Italy
| | - S Parrocchia
- UOC of Medical Direction S. Maria Goretti Hospital, Latina, Italy
| | - R Marrone
- UOC of Medical Direction S. Maria Goretti Hospital, Latina, Italy
| | - C Iavarone
- UOC of Anesthesia S. Maria Goretti Hospital, Latina, Italy
| | - G Arcangeli
- UOC of Radiotherapy S. Maria Goretti Hospital, Latina, Italy
| | - F Angelini
- Medical Oncology Unit, Regina Apostolorum Hospital, Albano, Rome, Italy
| | - C De Masi
- UOC of Diagnostic And Interventional Radiology, S. Maria Goretti Hospital, Latina, Italy
| | - C Ambrogi
- UOC of Diagnostic And Interventional Radiology, S. Maria Goretti Hospital, Latina, Italy
| | - S Travaini
- UOC Anatomia Patologica S. Maria Goretti Hospital, Latina, Italy
| | - A Calogero
- Dipartimento di Scienze e Biotecnologie Medico-Chirurgiche, Sapienza, Latina, Italy
| | - A Centra
- UOC of Information flows and process innovations ASL Latina, Italy
| | - F Ricci
- UOC Breast Unit Latina, S. Maria Goretti Hospital, Latina, Italy
| |
Collapse
|
7
|
Renier M, Busson A, Boulanger M, Piel C, Pons R, Tual S, Amadéo B, Meryet‐Figuiere M, Marcotullio E, Clin B, Baldi I, Lebailly P, Arveux P, Bara S, Bouvier AM, Busquet T, Colonna M, Coureau G, Delanoé M, Grosclaude P, Guizard AV, Herbrecht P, Laplante JJ, Lapotre‐Ledoux B, Launoy G, Lenoir D, Marrer E, Marcotullio E, Maynadié M, Molinié F, Monnereau A, Paumier A, Jarriges J, Thibaudier JM, Troussard X, Velten M, Wavelet E, Woronoff AS. Agricultural exposure and risk of soft tissue sarcomas and gastrointestinal stromal sarcoma in the
AGRIculture
and
CANcer
(
AGRICAN
) cohort. Int J Cancer 2022; 150:1792-1803. [DOI: 10.1002/ijc.33936] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2021] [Revised: 12/22/2021] [Accepted: 01/04/2022] [Indexed: 11/10/2022]
Affiliation(s)
- Marine Renier
- INSERM, UMR 1086 ANTICIPE, INSERM Caen France
- Université de Caen Normandie Caen France
| | - Amandine Busson
- INSERM, UMR 1086 ANTICIPE, INSERM Caen France
- Université de Caen Normandie Caen France
| | - Mathilde Boulanger
- INSERM, UMR 1086 ANTICIPE, INSERM Caen France
- Université de Caen Normandie Caen France
- Centre de Lutte Contre le Cancer François Baclesse Caen France
| | - Clément Piel
- Université de Bordeaux, Inserm, Bordeaux Population Health Research Center, team EPICENE, U1219 Bordeaux France
| | - Romain Pons
- INSERM, UMR 1086 ANTICIPE, INSERM Caen France
- Université de Caen Normandie Caen France
- Centre de Lutte Contre le Cancer François Baclesse Caen France
| | - Séverine Tual
- INSERM, UMR 1086 ANTICIPE, INSERM Caen France
- Université de Caen Normandie Caen France
- Centre de Lutte Contre le Cancer François Baclesse Caen France
| | - Brice Amadéo
- Université de Bordeaux, Inserm, Bordeaux Population Health Research Center, team EPICENE, U1219 Bordeaux France
- FRANCIM, Réseau national du registre des cancers Toulouse France
| | - Matthieu Meryet‐Figuiere
- INSERM, UMR 1086 ANTICIPE, INSERM Caen France
- Université de Caen Normandie Caen France
- Centre de Lutte Contre le Cancer François Baclesse Caen France
| | - Elisabeth Marcotullio
- Caisse Centrale de la Mutualité Sociale Agricole, Echelon National Santé sécurité au travail Bagnolet France
| | - Bénédicte Clin
- INSERM, UMR 1086 ANTICIPE, INSERM Caen France
- Université de Caen Normandie Caen France
- CHU de Caen Service de Pathologie Professionnelle Caen France
| | - Isabelle Baldi
- Université de Bordeaux, Inserm, Bordeaux Population Health Research Center, team EPICENE, U1219 Bordeaux France
- CHU de Bordeaux, Pôle de Santé Publique Service de Médecine du Travail et Pathologies professionnelles Bordeaux France
| | - Pierre Lebailly
- INSERM, UMR 1086 ANTICIPE, INSERM Caen France
- Université de Caen Normandie Caen France
- Centre de Lutte Contre le Cancer François Baclesse Caen France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Lopardo G, Belloso WH, Nannini E, Colonna M, Sanguineti S, Zylberman V, Muñoz L, Dobarro M, Lebersztein G, Farina J, Vidiella G, Bertetti A, Crudo F, Alzogaray MF, Barcelona L, Teijeiro R, Lambert S, Scublinsky D, Iacono M, Stanek V, Solari R, Cruz P, Casas MM, Abusamra L, Luciardi HL, Cremona A, Caruso D, de Miguel B, Lloret SP, Millán S, Kilstein Y, Pereiro A, Sued O, Cahn P, Spatz L, Goldbaum F. RBD-specific polyclonal F(ab´) 2 fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial. EClinicalMedicine 2021; 34:100843. [PMID: 33870149 PMCID: PMC8037439 DOI: 10.1016/j.eclinm.2021.100843] [Citation(s) in RCA: 26] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/20/2021] [Revised: 03/10/2021] [Accepted: 03/17/2021] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND passive immunotherapy is a therapeutic alternative for patients with COVID-19. Equine polyclonal antibodies (EpAbs) could represent a source of scalable neutralizing antibodies against SARS-CoV-2. METHODS we conducted a double-blind, randomized, placebo-controlled trial to assess efficacy and safety of EpAbs (INM005) in hospitalized adult patients with moderate and severe COVID-19 pneumonia in 19 hospitals of Argentina. Primary endpoint was improvement in at least two categories in WHO ordinal clinical scale at day 28 or hospital discharge (ClinicalTrials.gov number NCT04494984). FINDINGS between August 1st and October 26th, 2020, a total of 245 patients were enrolled. Enrolled patients were assigned to receive two blinded doses of INM005 (n = 118) or placebo (n = 123). Median age was 54 years old, 65•1% were male and 61% had moderate disease at baseline. Median time from symptoms onset to study treatment was 6 days (interquartile range 5 to 8). No statistically significant difference was noted between study groups on primary endpoint (risk difference [95% IC]: 5•28% [-3•95; 14•50]; p = 0•15). Rate of improvement in at least two categories was statistically significantly higher for INM005 at days 14 and 21 of follow-up. Time to improvement in two ordinal categories or hospital discharge was 14•2 (± 0•7) days in the INM005 group and 16•3 (± 0•7) days in the placebo group, hazard ratio 1•31 (95% CI 1•0 to 1•74). Subgroup analyses showed a beneficial effect of INM005 over severe patients and in those with negative baseline antibodies. Overall mortality was 6•9% the INM005 group and 11•4% in the placebo group (risk difference [95% IC]: 0•57 [0•24 to 1•37]). Adverse events of special interest were mild or moderate; no anaphylaxis was reported. INTERPRETATION Albeit not having reached the primary endpoint, we found clinical improvement of hospitalized patients with SARS-CoV-2 pneumonia, particularly those with severe disease.
Collapse
Affiliation(s)
- Gustavo Lopardo
- Hospital Municipal Dr. Bernardo Houssay, Pte Hipólito Yrigoyen 1757, Florida, Provincia de Buenos Aires, Argentina
- Fundación del Centro de Estudios Infectológicos (FUNCEI), French 3085, Ciudad Autónoma de Buenos Aires, Buenos Aires C1425, Argentina
| | - Waldo H. Belloso
- Department of Research, Hospital Italiano de Buenos Aires. Pres. Tte. Gral. Juan Domingo Perón 4190, Ciudad Autónoma de Buenos Aires, Buenos Aires C1199, Argentina
| | - Esteban Nannini
- Departamento de Enfermedades Infecciosas, Sanatorio Británico, Paraguay 40, Rosario, Santa Fé S2000 CVB, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina
| | - Mariana Colonna
- Inmunova S.A., 25 de mayo 1021, Villa Lynch, Gral. San Martín, Buenos Aires CP B1650HMP, Argentina
| | - Santiago Sanguineti
- Inmunova S.A., 25 de mayo 1021, Villa Lynch, Gral. San Martín, Buenos Aires CP B1650HMP, Argentina
| | - Vanesa Zylberman
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina
- Inmunova S.A., 25 de mayo 1021, Villa Lynch, Gral. San Martín, Buenos Aires CP B1650HMP, Argentina
| | - Luciana Muñoz
- Inmunova S.A., 25 de mayo 1021, Villa Lynch, Gral. San Martín, Buenos Aires CP B1650HMP, Argentina
| | - Martín Dobarro
- Sanatorio Sagrado Corazón (OSECAC), Bartolomé Mitre 1955, Ciudad Autónoma de Buenos Aires, Buenos Aires CP1039, Argentina
| | - Gabriel Lebersztein
- Sanatorio Sagrado Corazón (OSECAC), Bartolomé Mitre 1955, Ciudad Autónoma de Buenos Aires, Buenos Aires CP1039, Argentina
| | - Javier Farina
- Hospital de Alta Complejidad Cuenca Alta S.A.M.I.C. Dr. Néstor Carlos Kirchner, RP6, Cañuelas, Provincia de Buenos Aires, Argentina
| | - Gabriela Vidiella
- Sanatorio Agote. Dr. Luis Agote 2477, Ciudad Autónoma de Buenos Aires, Buenos Aires C1425 EOE, Argentina
| | - Anselmo Bertetti
- Sanatorio Güemes, Francisco Acuña de Figueroa 1240, Ciudad Autónoma de Buenos Aires, Buenos Aires C1180, Argentina
| | - Favio Crudo
- Hospital Municipal Emilio Zerboni, Moreno 90, San Antonio de Areco, Provincia de Buenos Aires B2760, Argentina
- Universidad Nacional de San Antonio de Areco, Av. Güiraldes 689, San Antonio de Areco, Provincia de Buenos Aires, Argentina
| | | | - Laura Barcelona
- Hospital Municipal Dr. Bernardo Houssay, Pte Hipólito Yrigoyen 1757, Florida, Provincia de Buenos Aires, Argentina
| | - Ricardo Teijeiro
- Hospital General de Agudos Dr. Ignacio Pirovano, Av. Monroe 3555, Ciudad Autónoma de Buenos Aires, Buenos Aires C1428, Argentina
| | - Sandra Lambert
- Hospital de Alta Complejidad El Cruce Néstor Kirchner, Av. Calchaquí 5401, Florencio Varela, Provincia de Buenos Aires, Argentina
| | - Darío Scublinsky
- Clínica Zabala. Av. Cabildo 1295, Ciudad Autónoma de Buenos Aires, Buenos Aires C1426 AAM, Argentina
| | - Marisa Iacono
- Hospital Provincial Neuquén Dr. Castro Rendón, Buenos Aires 450, Neuquén Q8300, Argentina
| | - Vanina Stanek
- Sección de Infectología, Servicio de Medicina Interna, Hospital Italiano de Buenos Aires. Pres. Tte. Gral. Juan Domingo Perón 4190, Ciudad Autónoma de Buenos Aires, Buenos Aires C1199, Argentina
| | - Rubén Solari
- Hospital de Infecciosas Francisco Javier Muñiz, Uspallata 2272, Ciudad Autónoma de Buenos Aires, Buenos Aires C1282, Argentina
| | - Pablo Cruz
- Centro Gallego de Buenos Aires, Av. Belgrano 2199, Ciudad Autónoma de Buenos Aires, Buenos Aires C1096, Argentina
| | - Marcelo Martín Casas
- Clínica Adventista Belgrano. Estomba 1710, Ciudad Autónoma de Buenos Aires, Buenos Aires C1430 EGF, Argentina
| | - Lorena Abusamra
- Hospital Municipal Dr. Diego Thompson, Avellaneda 33, Villa Lynch, Gral. San Martín, Buenos Aires B1650, Argentina
| | - Héctor Lucas Luciardi
- Hospital Centro de Salud Zenón J. Santillán, Av. Avellaneda 750, San Miguel de Tucumán, Tucumán T4000, Argentina
| | - Alberto Cremona
- Hospital Italiano La Plata, Av. 51, La Plata, Provincia de Buenos Aires B1900, Argentina
| | - Diego Caruso
- Hospital Español, Av. Belgrano 2975, Ciudad Autónoma de Buenos Aires, Buenos Aires C1209, Argentina
| | | | - Santiago Perez Lloret
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina
- Departamento de Docencia e Investigación, Facultad de Ciencias Médicas, Universidad Católica Argentina, Buenos Aires, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
- Universidad Abierta Interamericana, Centro de Altos Estudios en Ciencias Humanas y de la Salud (UAI-CAECIHS), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Av. San Juan 951, Ciudad Autónoma de Buenos Aires, Buenos Aires C1147 AAH, Argentina
| | - Susana Millán
- mAbxience, Manuel Pombo Angulo 28, 3rd floor, Madrid 28050, Spain
| | - Yael Kilstein
- PHV LATAM, AES, Amenábar 3851, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
| | - Ana Pereiro
- Fundación Mundo Sano, Paraguay 1535, Ciudad Autónoma de Buenos Aires, Buenos Aires C1061ABC, Argentina
| | - Omar Sued
- Fundación Huésped, Pasaje Ángel Peluffo 3932PB, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
| | - Pedro Cahn
- Fundación Huésped, Pasaje Ángel Peluffo 3932PB, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
| | - Linus Spatz
- Inmunova S.A., 25 de mayo 1021, Villa Lynch, Gral. San Martín, Buenos Aires CP B1650HMP, Argentina
| | - Fernando Goldbaum
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina
- Inmunova S.A., 25 de mayo 1021, Villa Lynch, Gral. San Martín, Buenos Aires CP B1650HMP, Argentina
- Fundación Instituto Leloir, IIBBA-CONICET. Av. Patricias Argentinas 435, Buenos Aires C1405BWE, Argentina
- CRIP - Centro de Rediseño e Ingeniería de Proteínas UNSAM Campus Miguelete. 25 de Mayo y Francia Villa Lynch, Gral. San Martín, Buenos Aires B1650HMK, Argentina
- Corresponding author at: Inmunova S.A., 25 de mayo 1021, Villa Lynch, Gral. San Martín, Buenos Aires CP B1650HMP, Argentina.
| | | |
Collapse
|
9
|
Fachi JL, Pral LP, dos Santos JAC, Codo AC, de Oliveira S, Felipe JS, Zambom FFF, Câmara NOS, Vieira PMMM, Colonna M, Vinolo MAR. Hypoxia enhances ILC3 responses through HIF-1α-dependent mechanism. Mucosal Immunol 2021; 14:828-841. [PMID: 33446906 PMCID: PMC8221997 DOI: 10.1038/s41385-020-00371-6] [Citation(s) in RCA: 30] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2020] [Revised: 12/08/2020] [Accepted: 12/08/2020] [Indexed: 02/04/2023]
Abstract
Group 3 innate lymphoid cells (ILC3) have a prominent role in the maintenance of intestine mucosa homeostasis. The hypoxia-inducible factor (HIF) is an important modulator of immune cell activation and a key mechanism for cellular adaptation to oxygen deprivation. However, its role on ILC3 is not well known. In this study, we investigated how a hypoxic environment modulates ILC3 response and the subsequent participation of HIF-1 signaling in this process. We found increased proliferation and activation of intestinal ILC3 at low oxygen levels, a response that was phenocopied when HIF-1α was chemically stabilized and was reversed when HIF-1 was blocked. The increased activation of ILC3 relied on a HIF-1α-dependent transcriptional program, but not on mTOR-signaling or a switch to glycolysis. HIF-1α deficiency in RORyt compartment resulted in impaired IL-17 and IL-22 production by ILC3 in vivo, which reflected in a lower expression of their target genes in the intestinal epithelium and an increased susceptibility to Clostridiodes difficile infection. Taken together, our results show that HIF-1α activation in intestinal ILC3 is relevant for their functions in steady state and infectious conditions.
Collapse
Affiliation(s)
- J. L. Fachi
- grid.411087.b0000 0001 0723 2494Laboratory of Immunoinflammation, Department of Genetics, Evolution, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, Brazil ,grid.4367.60000 0001 2355 7002Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO USA
| | - L. P. Pral
- grid.411087.b0000 0001 0723 2494Laboratory of Immunoinflammation, Department of Genetics, Evolution, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, Brazil
| | - J. A. C. dos Santos
- grid.411087.b0000 0001 0723 2494Laboratory of Immunoinflammation, Department of Genetics, Evolution, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, Brazil
| | - A. C. Codo
- grid.411087.b0000 0001 0723 2494Laboratory of Immunometabolism, Department of Genetics and Evolution, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, Brazil
| | - S. de Oliveira
- grid.411087.b0000 0001 0723 2494Laboratory of Immunoinflammation, Department of Genetics, Evolution, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, Brazil
| | - J. S. Felipe
- grid.411087.b0000 0001 0723 2494Laboratory of Immunoinflammation, Department of Genetics, Evolution, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, Brazil
| | - F. F. F. Zambom
- grid.11899.380000 0004 1937 0722Renal Division, Department of Clinical Medicine, Faculty of Medicine, University of São Paulo, São Paulo, Brazil
| | - N. O. S. Câmara
- grid.11899.380000 0004 1937 0722Renal Division, Department of Clinical Medicine, Faculty of Medicine, University of São Paulo, São Paulo, Brazil ,grid.11899.380000 0004 1937 0722Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil
| | - P. M. M. M. Vieira
- grid.411087.b0000 0001 0723 2494Laboratory of Immunometabolism, Department of Genetics and Evolution, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, Brazil ,Experimental Medicine Research Cluster, Campinas, Brazil ,grid.411087.b0000 0001 0723 2494Obesity and Comorbolities Research Center (OCRC), University of Campinas, Campinas, Brazil
| | - M. Colonna
- grid.4367.60000 0001 2355 7002Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO USA
| | - M. A. R. Vinolo
- grid.411087.b0000 0001 0723 2494Laboratory of Immunoinflammation, Department of Genetics, Evolution, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, Brazil ,Experimental Medicine Research Cluster, Campinas, Brazil ,grid.411087.b0000 0001 0723 2494Obesity and Comorbolities Research Center (OCRC), University of Campinas, Campinas, Brazil
| |
Collapse
|
10
|
Fachi JL, Pral LP, dos Santos JAC, Codo AC, de Oliveira S, Felipe JS, Zambom FFF, Câmara NOS, Vieira PMMM, Colonna M, Vinolo MAR. Correction to: Hypoxia enhances ILC3 responses through HIF-1α-dependent mechanism. Mucosal Immunol 2021; 14:973. [PMID: 33863998 PMCID: PMC8221993 DOI: 10.1038/s41385-021-00403-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Affiliation(s)
- J. L. Fachi
- grid.411087.b0000 0001 0723 2494Laboratory of Immunoinflammation, Department of Genetics, Evolution, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, Brazil ,grid.4367.60000 0001 2355 7002Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO USA
| | - L. P. Pral
- grid.411087.b0000 0001 0723 2494Laboratory of Immunoinflammation, Department of Genetics, Evolution, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, Brazil
| | - J. A. C. dos Santos
- grid.411087.b0000 0001 0723 2494Laboratory of Immunoinflammation, Department of Genetics, Evolution, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, Brazil
| | - A. C. Codo
- grid.411087.b0000 0001 0723 2494Laboratory of Immunometabolism, Department of Genetics and Evolution, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, Brazil
| | - S. de Oliveira
- grid.411087.b0000 0001 0723 2494Laboratory of Immunoinflammation, Department of Genetics, Evolution, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, Brazil
| | - J. S. Felipe
- grid.411087.b0000 0001 0723 2494Laboratory of Immunoinflammation, Department of Genetics, Evolution, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, Brazil
| | - F. F. F. Zambom
- grid.11899.380000 0004 1937 0722Renal Division, Department of Clinical Medicine, Faculty of Medicine, University of São Paulo, São Paulo, Brazil
| | - N. O. S. Câmara
- grid.11899.380000 0004 1937 0722Renal Division, Department of Clinical Medicine, Faculty of Medicine, University of São Paulo, São Paulo, Brazil ,grid.11899.380000 0004 1937 0722Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil
| | - P. M. M. M. Vieira
- grid.411087.b0000 0001 0723 2494Laboratory of Immunometabolism, Department of Genetics and Evolution, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, Brazil ,Experimental Medicine Research Cluster, Campinas, Brazil ,grid.411087.b0000 0001 0723 2494Obesity and Comorbolities Research Center (OCRC), University of Campinas, Campinas, Brazil
| | - M. Colonna
- grid.4367.60000 0001 2355 7002Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO USA
| | - M. A. R. Vinolo
- grid.411087.b0000 0001 0723 2494Laboratory of Immunoinflammation, Department of Genetics, Evolution, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, Brazil ,Experimental Medicine Research Cluster, Campinas, Brazil ,grid.411087.b0000 0001 0723 2494Obesity and Comorbolities Research Center (OCRC), University of Campinas, Campinas, Brazil
| |
Collapse
|
11
|
Toia F, Romeo M, Abate M, Avarotti E, Battiston B, Bruno G, Cannavò F F, Casamichele C, Colonna M, Catena N, Cherubino M, Coppolino S, Galvano N, Giuca G, Gullo S, Internullo G, Lazzerini A, Marcoccio I, Maruccia M, Melloni C, Pajardi G, Pugliese P, Risitano G, Spata G, Tripoli M, Troisi L, Tos P, Cordova A. Impact of COVID-19 on hand surgery in Italy: A comparison between the Northern and the Southern regions. Hand Surg Rehabil 2020; 40:139-144. [PMID: 33309793 PMCID: PMC7836699 DOI: 10.1016/j.hansur.2020.11.005] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/29/2020] [Revised: 11/24/2020] [Accepted: 11/26/2020] [Indexed: 12/03/2022]
Abstract
The aims of this study were to evaluate the impact of the COVID-19 pandemic on emergency and elective hand surgery in four Italian regions that had either a high (Lombardy and Piemonte) or a low (Sicilia and Puglia) COVID-19 case load to discuss problems and to elaborate strategies to improve treatment pathways. A panel of hand surgeons from these different regions compared and discussed data from the centers they work in. The COVID-19 pandemic had an enormous impact on both elective and emergency surgery in Italy, not only in highly affected regions but also – and paradoxically even at a higher extent – in regions with a low COVID-19 case load. A durable and flexible redesign of hand surgery activities should be promoted, while changing and hopefully increasing human resources and enhancing administrative support. Telematics must also be implemented, especially for delivering rehabilitation therapy.
Collapse
Affiliation(s)
- F Toia
- Plastic and Reconstructive Surgery, Department of Surgical Oncological and Oral Sciences, University of Palermo, Via Del Vespro 127, 90127, Palermo (PA), Italy.
| | - M Romeo
- Plastic and Reconstructive Surgery, Department of Surgical Oncological and Oral Sciences, University of Palermo, Via Del Vespro 127, 90127, Palermo (PA), Italy
| | - M Abate
- SSD di Ortopedia, ARNAS Garibaldi, Presidio di Nesima, Via Palermo 636, 95123, Catania (CT), Italy
| | - E Avarotti
- Department of Orthopedics and Traumatology, A.R.N.A.S. Piazza Santa Maria di Gesù 5, 95124, Catania (CT), Italy
| | - B Battiston
- Department of Orthopedics and Traumatology, Orthopedic and Trauma Center, AOU Città della Salute e della Scienza, Via Nizza 138, 10126, Torino (TO), Italy
| | - G Bruno
- Department of Orthopedics and Traumatology, A.O. Vittorio Emanuele, Via Plebiscito 632, 95122, Catania (CT), Italy
| | - F Cannavò F
- U.O.S.D. Plastic Surgery A.O. Papardo, Contrada Papardo, 98158, Messina (ME), Italy
| | - C Casamichele
- Department of Orthopedics and Traumatology, A.O. "G. Paolo II", Contrada Cisternazzi, 97010, Ragusa (RG), Italy
| | - M Colonna
- Plastic Surgery Unit, Department of Human Pathology, University of Messina, Via Consolare Valeria1, 98124, Messina (ME), Italy
| | - N Catena
- Pediatric Orthopedic and Traumatology Unit, Children's Hospital, AON SS Antonio e Biagio e Cesare Arrigo, Via Spalto Marengo 46, 15121, Alessandria (AL), Italy
| | - M Cherubino
- Department of Biotechnology and Life Sciences, Division of Plastic and Reconstructive Surgery, University of Insubria, Via Ravasi 2, 21100, Varese (VA), Italy
| | - S Coppolino
- Hospital S. Vincenzo, Contrada Sirina, 98039, Taormina (ME), Italy
| | - N Galvano
- Department of Orthopedics and Traumatology A.O.U.P." Paolo Giaccone", Via Del Vespro 127, 90127 Palermo (PA), Italy
| | - G Giuca
- Department of Orthopedics Ospedale Maggiore, Via Resistenza Partigiana, 97015, Modica (RG), Italy
| | - S Gullo
- Department of Hand Surgery and Traumatology, A.R.N.A.S., Piazza Nicola Leotta 4, 90127, Palermo (PA), Italy
| | - G Internullo
- Department of Orthopedics, Ospedale Gravina, Via Portosalvo 9, 95041, Caltagirone (CT), Italy
| | - A Lazzerini
- Hand Surgery and Microsurgery Unit, IRCCS Humanitas Clinical Institute, Via Alessandro Manzoni 6, 20089, Milano (MI), Italy
| | - I Marcoccio
- Orthopedic Microsurgery and Upper Limb Surgery, Istituto Clinico Città di Brescia, Via Bartolomeo Gualla 15, 25128, Brescia (BS), Italy
| | - M Maruccia
- Department of Emergency and Organ Transplantation, Plastic and Reconstructive Surgery and Burns Unit, University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70122, Bari (BR), Italy
| | - C Melloni
- Plastic and Reconstructive Surgery A.O. P. Borsellino, Contrada Cardilla 1, 91025, Marsala (TP), Italy
| | - G Pajardi
- Department of Clinical Sciences and Community Health, The University of Milan, Via Festa del Perdono 7, 20122, Milano (MI), Italy
| | - P Pugliese
- Plastic and Reconstructive Surgery, Department of Surgical Oncological and Oral Sciences, University of Palermo, Via Del Vespro 127, 90127, Palermo (PA), Italy
| | - G Risitano
- ABC Medical, Via Porto Salvo 2, 98121, Messina (ME), Italy
| | - G Spata
- Hand Surgery, Polyclinic Morgagni, Via del Bosco 105, 95030, Catania (CT), Italy
| | - M Tripoli
- Plastic and Reconstructive Surgery, Department of Surgical Oncological and Oral Sciences, University of Palermo, Via Del Vespro 127, 90127, Palermo (PA), Italy
| | - L Troisi
- Department of Clinical Sciences and Community Health, The University of Milan, Via Festa del Perdono 7, 20122, Milano (MI), Italy
| | - P Tos
- Hand Surgery and Reconstructive Microsurgery Unit, Orthopedic Institute G. Pini-CTO, Piazza Cardinale Andrea Ferrari 1, 20122, Milano (MI), Italy
| | - A Cordova
- Plastic and Reconstructive Surgery, Department of Surgical Oncological and Oral Sciences, University of Palermo, Via Del Vespro 127, 90127, Palermo (PA), Italy
| |
Collapse
|
12
|
Mack M, Brestoff J, Berrien-Elliott M, Yang T, Trier A, Collins P, Niu H, Bodet N, Wagner J, Park E, Xu A, Wang F, McCullen M, Chibnall R, Council M, Margolis D, Sheinbein D, Vivier E, Lovato P, Cella M, Colonna M, Yokoyama W, Oltz E, Fehniger T, Kim B. 852 Natural killer cell deficiency reveals a novel immunotherapy strategy for atopic dermatitis. J Invest Dermatol 2020. [DOI: 10.1016/j.jid.2020.03.868] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
13
|
Ciardiello A, Asai M, Caccia B, Cirrone GAP, Colonna M, Dotti A, Faccini R, Giagu S, Messina A, Napolitani P, Pandola L, Wright DH, Mancini-Terracciano C. Preliminary results in using Deep Learning to emulate BLOB, a nuclear interaction model. Phys Med 2020; 73:65-72. [PMID: 32330813 DOI: 10.1016/j.ejmp.2020.04.005] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/07/2019] [Revised: 03/17/2020] [Accepted: 04/03/2020] [Indexed: 11/27/2022] Open
Abstract
PURPOSE A reliable model to simulate nuclear interactions is fundamental for Ion-therapy. We already showed how BLOB ("Boltzmann-Langevin One Body"), a model developed to simulate heavy ion interactions up to few hundreds of MeV/u, could simulate also 12C reactions in the same energy domain. However, its computation time is too long for any medical application. For this reason we present the possibility of emulating it with a Deep Learning algorithm. METHODS The BLOB final state is a Probability Density Function (PDF) of finding a nucleon in a position of the phase space. We discretised this PDF and trained a Variational Auto-Encoder (VAE) to reproduce such a discrete PDF. As a proof of concept, we developed and trained a VAE to emulate BLOB in simulating the interactions of 12C with 12C at 62 MeV/u. To have more control on the generation, we forced the VAE latent space to be organised with respect to the impact parameter (b) training a classifier of b jointly with the VAE. RESULTS The distributions obtained from the VAE are similar to the input ones and the computation time needed to use the VAE as a generator is negligible. CONCLUSIONS We show that it is possible to use a Deep Learning approach to emulate a model developed to simulate nuclear reactions in the energy range of interest for Ion-therapy. We foresee the implementation of the generation part in C++ and to interface it with the most used Monte Carlo toolkit: Geant4.
Collapse
Affiliation(s)
- A Ciardiello
- Dip. Fisica, Sapienza Univ. di Roma, Rome, Italy; INFN Sezione di Roma, Rome, Italy
| | - M Asai
- SLAC National Accelerator Laboratory, Menlo Park, United States
| | - B Caccia
- National Center for Radiation Protection and Computational Physics, Istituto Superiore di Sanitá, Italy
| | | | - M Colonna
- INFN, Laboratori Nazionali del Sud, Catania, Italy
| | - A Dotti
- SLAC National Accelerator Laboratory, Menlo Park, United States
| | - R Faccini
- Dip. Fisica, Sapienza Univ. di Roma, Rome, Italy; INFN Sezione di Roma, Rome, Italy
| | - S Giagu
- Dip. Fisica, Sapienza Univ. di Roma, Rome, Italy; INFN Sezione di Roma, Rome, Italy
| | - A Messina
- Dip. Fisica, Sapienza Univ. di Roma, Rome, Italy; INFN Sezione di Roma, Rome, Italy
| | - P Napolitani
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - L Pandola
- INFN, Laboratori Nazionali del Sud, Catania, Italy
| | - D H Wright
- SLAC National Accelerator Laboratory, Menlo Park, United States
| | - C Mancini-Terracciano
- Dip. Fisica, Sapienza Univ. di Roma, Rome, Italy; INFN Sezione di Roma, Rome, Italy.
| |
Collapse
|
14
|
Zylberman V, Sanguineti S, Pontoriero AV, Higa SV, Cerutti ML, Morrone Seijo SM, Pardo R, Muñoz L, Acuña Intrieri ME, Alzogaray VA, Avaro MM, Benedetti E, Berguer PM, Bocanera L, Bukata L, Bustelo MS, Campos AM, Colonna M, Correa E, Cragnaz L, Dattero ME, Dellafiore M, Foscaldi S, González JV, Guerra LL, Klinke S, Labanda MS, Lauché C, López JC, Martínez AM, Otero LH, Peyric EH, Ponziani PF, Ramondino R, Rinaldi J, Rodríguez S, Russo JE, Russo ML, Saavedra SL, Seigelchifer M, Sosa S, Vilariño C, López Biscayart P, Corley E, Spatz L, Baumeister EG, Goldbaum FA. Development of a hyperimmune equine serum therapy for COVID-19 in Argentina. Medicina (B Aires) 2020; 80 Suppl 3:1-6. [PMID: 32658841] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/11/2023] Open
Abstract
The disease named COVID-19, caused by the SARS-CoV-2 coronavirus, is currently generating a global pandemic. Vaccine development is no doubt the best long-term immunological approach, but in the current epidemiologic and health emergency there is a need for rapid and effective solutions. Convalescent plasma is the only antibody-based therapy available for COVID-19 patients to date. Equine polyclonal antibodies (EpAbs) put forward a sound alternative. The new generation of processed and purified EpAbs containing highly purified F(ab')2 fragments demonstrated to be safe and well tolerated. EpAbs are easy to manufacture allowing a fast development and scaling up for a treatment. Based on these ideas, we present a new therapeutic product obtained after immunization of horses with the receptor-binding domain of the viral Spike glycoprotein. Our product shows around 50 times more potency in in vitro seroneutralization assays than the average of convalescent plasma. This result may allow us to test the safety and efficacy of this product in a phase 2/3 clinical trial to be conducted in July 2020 in the metropolitan area of Buenos Aires, Argentina.
Collapse
Affiliation(s)
- Vanesa Zylberman
- Inmunova S.A., San Martín, Provincia de Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina
| | | | - Andrea V Pontoriero
- Servicio Virosis Respiratorias INEI-ANLIS Malbrán, Laboratorio Nacional de Referencia de Enfermedades Respiratorias Virales, Centro Nacional de Influenza de OMS, Buenos Aires, Argentina
| | - Sandra V Higa
- Instituto Biológico Argentino S.A.I.C., Buenos Aires, Argentina
| | - María L Cerutti
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina
- CRIP -Centro de Rediseño e Ingeniería de Proteínas UNSAM, Campus Miguelete, San Martín, Provincia de Buenos Aires, Argentina
| | | | - Romina Pardo
- Inmunova S.A., San Martín, Provincia de Buenos Aires, Argentina
| | - Luciana Muñoz
- Inmunova S.A., San Martín, Provincia de Buenos Aires, Argentina
| | - María E Acuña Intrieri
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina
- CRIP -Centro de Rediseño e Ingeniería de Proteínas UNSAM, Campus Miguelete, San Martín, Provincia de Buenos Aires, Argentina
| | - Vanina A Alzogaray
- Laboratorio de Inmunología y Microbiología Molecular, Fundación Instituto Leloir, IIBBA-CONICET, Buenos Aires, Argentina
| | - Martín M Avaro
- Servicio Virosis Respiratorias INEI-ANLIS Malbrán, Laboratorio Nacional de Referencia de Enfermedades Respiratorias Virales, Centro Nacional de Influenza de OMS, Buenos Aires, Argentina
| | - Estefanía Benedetti
- Servicio Virosis Respiratorias INEI-ANLIS Malbrán, Laboratorio Nacional de Referencia de Enfermedades Respiratorias Virales, Centro Nacional de Influenza de OMS, Buenos Aires, Argentina
| | - Paula M Berguer
- Laboratorio de Inmunología y Microbiología Molecular, Fundación Instituto Leloir, IIBBA-CONICET, Buenos Aires, Argentina
| | | | - Lucas Bukata
- Inmunova S.A., San Martín, Provincia de Buenos Aires, Argentina
| | | | - Ana M Campos
- Servicio Virosis Respiratorias INEI-ANLIS Malbrán, Laboratorio Nacional de Referencia de Enfermedades Respiratorias Virales, Centro Nacional de Influenza de OMS, Buenos Aires, Argentina
| | - Mariana Colonna
- Inmunova S.A., San Martín, Provincia de Buenos Aires, Argentina
| | - Elisa Correa
- mAbxience, Munro, Provincia de Buenos Aires, Argentina
| | - Lucía Cragnaz
- mAbxience, Munro, Provincia de Buenos Aires, Argentina
| | - María E Dattero
- Servicio Virosis Respiratorias INEI-ANLIS Malbrán, Laboratorio Nacional de Referencia de Enfermedades Respiratorias Virales, Centro Nacional de Influenza de OMS, Buenos Aires, Argentina
| | | | - Sabrina Foscaldi
- Laboratorio de Inmunología y Microbiología Molecular, Fundación Instituto Leloir, IIBBA-CONICET, Buenos Aires, Argentina
| | | | | | - Sebastián Klinke
- Laboratorio de Inmunología y Microbiología Molecular, Fundación Instituto Leloir, IIBBA-CONICET, Buenos Aires, Argentina
| | - María S Labanda
- Laboratorio de Inmunología y Microbiología Molecular, Fundación Instituto Leloir, IIBBA-CONICET, Buenos Aires, Argentina
| | | | - Juan C López
- Instituto Biológico Argentino S.A.I.C., Buenos Aires, Argentina
| | | | - Lisandro H Otero
- Laboratorio de Inmunología y Microbiología Molecular, Fundación Instituto Leloir, IIBBA-CONICET, Buenos Aires, Argentina
| | - Elías H Peyric
- Instituto Biológico Argentino S.A.I.C., Buenos Aires, Argentina
| | | | | | - Jimena Rinaldi
- Laboratorio de Inmunología y Microbiología Molecular, Fundación Instituto Leloir, IIBBA-CONICET, Buenos Aires, Argentina
| | | | - Javier E Russo
- Instituto Biológico Argentino S.A.I.C., Buenos Aires, Argentina
| | - Mara L Russo
- Servicio Virosis Respiratorias INEI-ANLIS Malbrán, Laboratorio Nacional de Referencia de Enfermedades Respiratorias Virales, Centro Nacional de Influenza de OMS, Buenos Aires, Argentina
| | | | | | - Santiago Sosa
- Laboratorio de Inmunología y Microbiología Molecular, Fundación Instituto Leloir, IIBBA-CONICET, Buenos Aires, Argentina
| | - Claudio Vilariño
- >CRIP -Centro de Rediseño e Ingeniería de Proteínas UNSAM, Campus Miguelete, San Martín, Provincia de Buenos Aires, Argentina
| | | | | | - Linus Spatz
- Inmunova S.A., San Martín, Provincia de Buenos Aires, Argentina
| | - Elsa G Baumeister
- Servicio Virosis Respiratorias INEI-ANLIS Malbrán, Laboratorio Nacional de Referencia de Enfermedades Respiratorias Virales, Centro Nacional de Influenza de OMS, Buenos Aires, Argentina
| | - Fernando A Goldbaum
- Inmunova S.A., San Martín, Provincia de Buenos Aires, Argentina
- CRIP -Centro de Rediseño e Ingeniería de Proteínas UNSAM, Campus Miguelete, San Martín, Provincia de Buenos Aires, Argentina
- Laboratorio de Inmunología y Microbiología Molecular, Fundación Instituto Leloir, IIBBA-CONICET, Buenos Aires, Argentina
| |
Collapse
|
15
|
Mancini-Terracciano C, Asai M, Caccia B, Cirrone GAP, Dotti A, Faccini R, Napolitani P, Pandola L, Wright DH, Colonna M. Preliminary results coupling "Stochastic Mean Field" and "Boltzmann-Langevin One Body" models with Geant4. Phys Med 2019; 67:116-122. [PMID: 31706147 DOI: 10.1016/j.ejmp.2019.10.026] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/31/2019] [Revised: 10/02/2019] [Accepted: 10/13/2019] [Indexed: 11/15/2022] Open
Abstract
PURPOSE Monte Carlo (MC) simulations are widely used for medical applications and nuclear reaction models are fundamental for the simulation of the particle interactions with patients in ion therapy. Therefore, it is of utmost importance to have reliable models in MC simulations for such interactions. Geant4 is one of the most used toolkits for MC simulation. However, its models showed severe limitations in reproducing the yields measured in the interaction of ion beams below 100 MeV/u with thin targets. For this reason, we interfaced two models, SMF ("Stochastic Mean Field") and BLOB ("Boltzmann-Langevin One Body"), dedicated to simulate such reactions, with Geant4. METHODS Both SMF and BLOB are semi-classical, one-body approaches to solve the Boltzmann-Langevin equation. They include an identical treatment of the mean-field propagation, on the basis of the same effective interaction, but they differ in the way fluctuations are included. Furthermore, we tested a correction to the excitation energy calculated for the light fragments emerging from the simulations and a simple coalescence model. RESULTS While both SMF and BLOB have been developed to simulate heavy ion interactions, they show very good results in reproducing the experimental yields of light fragments, up to alpha particles, obtained in the interaction of 12C with a thin carbon target at 62 MeV/u. CONCLUSIONS BLOB in particular gives promising results and this stresses the importance of integrating it into the Geant4 toolkit.
Collapse
Affiliation(s)
- C Mancini-Terracciano
- Dip. Fisica, Sapienza Univ. di Roma, Rome, Italy; INFN Sezione di Roma, Rome, Italy.
| | - M Asai
- SLAC National Accelerator Laboratory, Menlo Park, United States
| | - B Caccia
- National Center for Radiation Protection and Computational Physics, Istituto Superiore di Sanit, Italy
| | | | - A Dotti
- SLAC National Accelerator Laboratory, Menlo Park, United States
| | - R Faccini
- Dip. Fisica, Sapienza Univ. di Roma, Rome, Italy; INFN Sezione di Roma, Rome, Italy
| | - P Napolitani
- IPN, CNRS/IN2P3, Université Paris-Sud 11, UniversitéParis-Saclay, 91406 Orsay Cedex, France
| | - L Pandola
- INFN, Laboratori Nazionali del Sud, Catania, Italy
| | - D H Wright
- SLAC National Accelerator Laboratory, Menlo Park, United States
| | - M Colonna
- INFN, Laboratori Nazionali del Sud, Catania, Italy
| |
Collapse
|
16
|
Alla A, Mounier M, Romain G, Remontet L, Bossard N, Maynadié M, Boussari O, Colonna M, Jooste V. Impact de l’âge et de l’année sur les indicateurs de survie nette et de guérison par sous-type de leucémie aiguë myéloïde en France entre 1989 et 2010. Rev Epidemiol Sante Publique 2019. [DOI: 10.1016/j.respe.2018.11.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
17
|
Pastrone L, Corsetti MT, Depaoli L, Sampò S, Colonna M, Rocchetti A. An atypical occurrence of Aspergillosis in leukemic patient: Brief description of a clinical case. J Mycol Med 2018; 28:655-658. [DOI: 10.1016/j.mycmed.2018.10.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2018] [Revised: 09/13/2018] [Accepted: 10/05/2018] [Indexed: 11/27/2022]
|
18
|
Piel C, Pouchieu C, Migault L, Béziat B, Boulanger M, Bureau M, Carles C, Grüber A, Lecluse Y, Rondeau V, Schwall X, Tual S, Lebailly P, Baldi I, Arveux P, Bara S, Bouvier AM, Busquet T, Colonna M, Coureau G, Delanoé M, Grosclaude P, Guizard AV, Herbrecht P, Laplante JJ, Lapotre-Ledoux B, Launoy G, Lenoir D, Marrer E, Marcotullio E, Maynadié M, Molinié F, Monnereau A, Paumier A, Pouzet P, Thibaudier JM, Troussard X, Velten M, Wavelet E, Woronoff AS. Increased risk of central nervous system tumours with carbamate insecticide use in the prospective cohort AGRICAN. Int J Epidemiol 2018; 48:512-526. [DOI: 10.1093/ije/dyy246] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/15/2018] [Indexed: 12/20/2022] Open
Affiliation(s)
| | - Camille Pouchieu
- EPICENE Team
- Registre des tumeurs primitives du système nerveux central de la Gironde, Inserm U1219, Bordeaux Population Health Research Center, University of Bordeaux, Bordeaux, France
| | | | | | - Mathilde Boulanger
- Inserm U1086, Anticipe Axe Cancers et Préventions, Caen, France
- Université de Caen-Normandie, Caen, France
- Centre de Lutte Contre le Cancer François Baclesse, Caen, France
| | | | - Camille Carles
- EPICENE Team
- CHU de Bordeaux, Service de Médecine du Travail et Pathologies Professionnelles, Bordeaux, France
| | - Anne Grüber
- EPICENE Team
- Registre des tumeurs primitives du système nerveux central de la Gironde, Inserm U1219, Bordeaux Population Health Research Center, University of Bordeaux, Bordeaux, France
| | - Yannick Lecluse
- Inserm U1086, Anticipe Axe Cancers et Préventions, Caen, France
- Université de Caen-Normandie, Caen, France
- Centre de Lutte Contre le Cancer François Baclesse, Caen, France
| | | | | | - Séverine Tual
- Inserm U1086, Anticipe Axe Cancers et Préventions, Caen, France
- Université de Caen-Normandie, Caen, France
- Centre de Lutte Contre le Cancer François Baclesse, Caen, France
| | - Pierre Lebailly
- Inserm U1086, Anticipe Axe Cancers et Préventions, Caen, France
- Université de Caen-Normandie, Caen, France
- Centre de Lutte Contre le Cancer François Baclesse, Caen, France
| | - Isabelle Baldi
- EPICENE Team
- Registre des tumeurs primitives du système nerveux central de la Gironde, Inserm U1219, Bordeaux Population Health Research Center, University of Bordeaux, Bordeaux, France
- CHU de Bordeaux, Service de Médecine du Travail et Pathologies Professionnelles, Bordeaux, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Seigneurin A, Delafosse P, Trétarre B, Woronoff AS, Velten M, Grosclaude P, Guizard AV, Lapôtre-Ledoux B, Bara S, Molinié F, Colonna M. Are comorbidities associated with long-term survival of lung cancer? A population-based cohort study from French cancer registries. BMC Cancer 2018; 18:1091. [PMID: 30419850 PMCID: PMC6233579 DOI: 10.1186/s12885-018-5000-7] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2017] [Accepted: 10/28/2018] [Indexed: 11/10/2022] Open
Abstract
Background Survival rates of lung cancer remains poor and the impact of comorbidities on the prognosis is discussed. The objective of this study was to assess if the Charlson Comorbidity Index (CCI) was associated with 8-year survival rates by histological type. Methods A cohort study was conducted using randomly selected cases from 10 French cancer registries. Net survival rates were computed using the Pohar-Perme estimator of the net cumulative rate. Three Cox models were independently built for adenocarcinomas, squamous cell and small cell cancers to estimate prognostic factors including CCI grade. Results A total of 646 adenocarcinomas, 524 squamous cell and 233 small cell cancers were included in the analysis. The net 8-year survival rate ranged from 12.6% (95% CI: 9.8–15.4%) for adenocarcinomas and 13.4% (95% CI: 10.1–16.7%) for squamous cell carcinomas, to 3.7% (95% CI: 1.1–6.3%) for small cell cancers. Observed and net survival rates decreased for CCI grades ≥3 for all histological group considered. After adjustment for sex, age group, stage and diagnostic mode, CCI grades 1 (HR = 1.6 [95% CI: 1.1–2.3]), 2 (HR = 1.7 [95% CI: 1.1–2.7]) and ≥ 3 (HR = 2.7 [95% CI: 1.7–4.4]) were associated with lower survival rates only for small cell cancers. Conclusion After adjustment for age, sex, stage and diagnostic mode, the presence of comorbidity based on CCI grades 1–2 and ≥ 3 was associated with lower survival rates for small cell cancers whereas no differences were observed for adenocarcinomas and squamous cell cancers.
Collapse
Affiliation(s)
- A Seigneurin
- Isère Cancer Registry, CHU Grenoble, Grenoble, France. .,Grenoble Alpes University, Techniques de l'Ingénierie Médicale et de la Complexité - Informatique Mathématiques et Applications Grenoble, Unité Mixte de Recherche 5525, Grenoble, France. .,Medical evaluation unit, CHU Grenoble Alpes, Grenoble, France.
| | - P Delafosse
- Isère Cancer Registry, CHU Grenoble, Grenoble, France
| | - B Trétarre
- Hérault Cancer Registry, Montpellier, France
| | - A S Woronoff
- Doubs Cancer Registry, CHU Besançon, Besançon, France
| | - M Velten
- Bas-Rhin Cancer Registry, Université de Strasbourg, Strasbourg, France
| | - P Grosclaude
- Tarn Cancer Registry, Institut Claudius Regaud, IUCT-O, Registre des cancer du Tarn, Toulouse, France.,, LEASP - UMR 1027 Inserm-Université Toulouse III, Toulouse, France
| | - A V Guizard
- Calvados Cancer Registry, CLCC François Baclesse, Caen, France
| | | | - S Bara
- Manche Cancer Registry, CH du Cotentin, Cherbourg en Cotentin, France
| | - F Molinié
- Loire-Atlantique and Vendée Cancer Registry, CHU Nantes, Nantes, France
| | - M Colonna
- Isère Cancer Registry, CHU Grenoble, Grenoble, France
| |
Collapse
|
20
|
Colonna M, Boussari O, Cowppli-Bony A, Delafosse P, Romain G, Grosclaude P, Jooste V. Erratum to "Time trends and short term projections of cancer prevalence in France" [Cancer Epidemiol. 56 (2018) 97-105]. Cancer Epidemiol 2018; 57:158-159. [PMID: 30293874 DOI: 10.1016/j.canep.2018.10.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
- M Colonna
- Isere Cancer Registry, CHU Grenoble-Alpes, F-38043, Grenoble, France; FRANCIM Network, F-31073, Toulouse, France.
| | - O Boussari
- Digestive Cancer Registry of Burgundy, INSERM UMR 1231, University Hospital of Dijon, University of Burgundy, F-21079, Dijon, France
| | - A Cowppli-Bony
- FRANCIM Network, F-31073, Toulouse, France; Loire-Atlantique Vendée Cancer Registry, F-44093, Nantes, France
| | - P Delafosse
- Isere Cancer Registry, CHU Grenoble-Alpes, F-38043, Grenoble, France; FRANCIM Network, F-31073, Toulouse, France
| | - G Romain
- Digestive Cancer Registry of Burgundy, INSERM UMR 1231, University Hospital of Dijon, University of Burgundy, F-21079, Dijon, France
| | - P Grosclaude
- FRANCIM Network, F-31073, Toulouse, France; Tarn Cancer Registry, Claudius Regaud Institute, IUCT-O, F-31059, Toulouse, France
| | - V Jooste
- FRANCIM Network, F-31073, Toulouse, France; Digestive Cancer Registry of Burgundy, INSERM UMR 1231, University Hospital of Dijon, University of Burgundy, F-21079, Dijon, France
| | | |
Collapse
|
21
|
Ameri A, Moradi Tuchayi S, Zaalberg A, Ngo K, Cunningham T, Colonna M, Mathis D, Lee R, Demehri S. 132 IL-33 - T regulatory cell axis triggers development of a cancer-promoting immune environment in chronic inflammation. J Invest Dermatol 2018. [DOI: 10.1016/j.jid.2018.03.137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
22
|
Abstract
Von Meyenburg complexes (multiple bile-duct microhamartomas) are formed by numerous groups of small bile-ducts comprised in a fibrous stroma. Together with other bile-duct hamartomas, such as cholangioadenomas and cholangiocystadenomas (often included under the heading of von Meyenburg complexes), they are closely related pathogenetically to polycystic disease of the liver. The frequent association of other developmental anomalies, both of the liver (hemangiomas) and of other organs (namely cystic disease of the kidney), confirms the malformative origin. The possible malignant transformation of von Meyenburg complexes has recently been reported. Seven cases of hepatic cholangiohamartomas are reported: three multiple bile-duct microhamartomas (1 associated with cystic disease of the kidney), two cholangioadenomas (1 associated with hepatic hemangioma) and two biliary cystadenomas.
Collapse
|
23
|
Fondain M, Dereure O, Uhry Z, Guizard A, Woronoff A, Colonna M, Molinie F, Bara S, Velten M, Marrer E, Grosclaude P, Lapôtre-Ledoux B, Tretarre B, Guillot B. Merkel cell carcinoma in France: a registries-based, comprehensive epidemiological survey. J Eur Acad Dermatol Venereol 2018; 32:1292-1296. [DOI: 10.1111/jdv.14798] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2017] [Accepted: 01/04/2018] [Indexed: 11/30/2022]
Affiliation(s)
- M. Fondain
- Department of Dermatology; Montpellier University; CHU Saint-Eloi; Montpellier France
- CARADERM Network
| | - O. Dereure
- Department of Dermatology; Montpellier University; CHU Saint-Eloi; Montpellier France
| | - Z. Uhry
- Institut de Veille Sanitaire; Service de Biostatistiques des Hospices Civils de Lyon; Lyon France
| | - A.V. Guizard
- FRANCIM Network of French Cancer Registries; Toulouse France
- Registre Général des Tumeurs du Calvados; Caen France
| | - A.S. Woronoff
- FRANCIM Network of French Cancer Registries; Toulouse France
- Registre des Tumeurs du Doubs et du Territoire de Belfort; CHRU Besançon; Besançon France
| | - M. Colonna
- FRANCIM Network of French Cancer Registries; Toulouse France
- Registre des Cancers de l'Isère; Grenoble France
| | - F. Molinie
- FRANCIM Network of French Cancer Registries; Toulouse France
- Registre des Cancers de Loire-Atlantique-Vendée; Nantes France
| | - S. Bara
- FRANCIM Network of French Cancer Registries; Toulouse France
- Registre des Cancers de la Manche; Cherbourg France
| | - M. Velten
- FRANCIM Network of French Cancer Registries; Toulouse France
- Registre des Cancers du Bas-Rhin; Strasbourg France
| | - E. Marrer
- Registre des Cancers du Haut-Rhin; Mulhouse France
| | - P. Grosclaude
- FRANCIM Network of French Cancer Registries; Toulouse France
- Registre des Cancers du Tarn; Albi France
| | - B. Lapôtre-Ledoux
- FRANCIM Network of French Cancer Registries; Toulouse France
- Registre des Cancers de la Somme; Amiens France
| | - B. Tretarre
- FRANCIM Network of French Cancer Registries; Toulouse France
- Registre des Tumeurs de l'Hérault; EA 2415 Institut du Cancer de Montpellier Montpellier France
| | - B. Guillot
- Department of Dermatology; Montpellier University; CHU Saint-Eloi; Montpellier France
- CARADERM Network
| |
Collapse
|
24
|
Hiriart Y, Pardo R, Bukata L, Lauché C, Muñoz L, Colonna M, Goldbaum F, Sanguineti S, Zylberman V. [Development of a product anti-Shiga toxin for prevention of the hemolytic uremic syndrome]. Medicina (B Aires) 2018; 78:107-112. [PMID: 29659360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/08/2023] Open
Abstract
The typical hemolytic uremic syndrome (HUS) is an orphan disease caused by Shiga toxin(Stx) producing Escherichia coli strains and characterized by acute kidney damage, microangiopathic hemolytic anemia and low platelet count. It is endemic in Argentina, the country with the highest incidence of HUS in the world. Stx is essential for its development and therefore, HUS is considered a toxemic non-bacteremic disorder, which could be treated with antibodies. Herein we describe the development of a new treatment capable of neutralizing the toxic effect of Stx and its variants. The treatment consists of F(ab')2 fragments from an equine antiserum whose efficacy and potency against Stx1 and Stx2 were proved in different preclinical models. The product was shown to be safe in animals. Furthermore, the anti-Stx F(ab')2 pharmacokinetic was shown to be similar to that of analogous compounds and a therapeutic window for its administration was determined. Altogether, these preclinical results warrant testing in humans. The phase I clinical trial will be performed at the Hospital Italiano in Buenos Aires to evaluate the safety and pharmacokinetics of the product in healthy adult volunteers. Based on the results of this study, a phase II clinical trial will be planned in pediatric patients diagnosed with infection by Stx-producing E. coli strains.
Collapse
|
25
|
Matz M, Coleman MP, Sant M, Chirlaque MD, Visser O, Gore M, Allemani C, Bouzbid S, Hamdi-Chérif M, Zaidi Z, Bah E, Swaminathan R, Nortje S, El Mistiri M, Bayo S, Malle B, Manraj S, Sewpaul-Sungkur R, Fabowale A, Ogunbiyi O, Bradshaw D, Somdyala N, Stefan D, Abdel-Rahman M, Jaidane L, Mokni M, Kumcher I, Moreno F, González M, Laura E, Espinola S, Calabrano G, Carballo Quintero B, Fita R, Garcilazo D, Giacciani P, Diumenjo M, Laspada W, Green M, Lanza M, Ibañez S, Lima C, Lobo de Oliveira E, Daniel C, Scandiuzzi C, De Souza P, Melo C, Del Pino K, Laporte C, Curado M, de Oliveira J, Veneziano C, Veneziano D, Latorre M, Tanaka L, Azevedo e Silva G, Galaz J, Moya J, Herrmann D, Vargas S, Herrera V, Uribe C, Bravo L, Arias-Ortiz N, Jurado D, Yépez M, Galán Y, Torres P, Martínez-Reyes F, Pérez-Meza M, Jaramillo L, Quinto R, Cueva P, Yépez J, Torres-Cintrón C, Tortolero-Luna G, Alonso R, Barrios E, Nikiforuk C, Shack L, Coldman A, Woods R, Noonan G, Turner D, Kumar E, Zhang B, McCrate F, Ryan S, Hannah H, Dewar R, MacIntyre M, Lalany A, Ruta M, Marrett L, Nishri D, McClure C, Vriends K, Bertrand C, Louchini R, Robb K, Stuart-Panko H, Demers S, Wright S, George J, Shen X, Brockhouse J, O'Brien D, Ward K, Almon L, Bates J, Rycroft R, Mueller L, Phillips C, Brown H, Cromartie B, Schwartz A, Vigneau F, MacKinnon J, Wohler B, Bayakly A, Clarke C, Glaser S, West D, Green M, Hernandez B, Johnson C, Jozwik D, Charlton M, Lynch C, Huang B, Tucker T, Deapen D, Liu L, Hsieh M, Wu X, Stern K, Gershman S, Knowlton R, Alverson J, Copeland G, Rogers D, Lemons D, Williamson L, Hood M, Hosain G, Rees J, Pawlish K, Stroup A, Key C, Wiggins C, Kahn A, Schymura M, Leung G, Rao C, Giljahn L, Warther B, Pate A, Patil M, Schubert S, Rubertone J, Slack S, Fulton J, Rousseau D, Janes T, Schwartz S, Bolick S, Hurley D, Richards J, Whiteside M, Nogueira L, Herget K, Sweeney C, Martin J, Wang S, Harrelson D, Keitheri Cheteri M, Farley S, Hudson A, Borchers R, Stephenson L, Espinoza J, Weir H, Edwards B, Wang N, Yang L, Chen J, Song G, Gu X, Zhang P, Ge H, Zhao D, Zhang J, Zhu F, Tang J, Shen Y, Wang J, Li Q, Yang X, Dong J, Li W, Cheng L, Chen J, Huang Q, Huang S, Guo G, Wei K, Chen W, Zeng H, Demetriou A, Pavlou P, Mang W, Ngan K, Swaminathan R, Kataki A, Krishnatreya M, Jayalekshmi P, Sebastian P, Sapkota S, Verma Y, Nandakumar A, Suzanna E, Keinan-Boker L, Silverman B, Ito H, Nakagawa H, Hattori M, Kaizaki Y, Sugiyama H, Utada M, Katayama K, Narimatsu H, Kanemura S, Koike T, Miyashiro I, Yoshii M, Oki I, Shibata A, Matsuda T, Nimri O, Ab Manan A, Bhoo-Pathy N, Tuvshingerel S, Chimedsuren O, Al Khater A, El Mistiri M, Al-Eid H, Jung K, Won Y, Chiang C, Lai M, Suwanrungruang K, Wiangnon S, Daoprasert K, Pongnikorn D, Geater S, Sriplung H, Eser S, Yakut C, Hackl M, Mühlböck H, Oberaigner W, Zborovskaya A, Aleinikova O, Henau K, Van Eycken L, Dimitrova N, Valerianova Z, Šekerija M, Zvolský M, Engholm G, Storm H, Innos K, Mägi M, Malila N, Seppä K, Jégu J, Velten M, Cornet E, Troussard X, Bouvier A, Faivre J, Guizard A, Bouvier V, Launoy G, Arveux P, Maynadié M, Mounier M, Fournier E, Woronoff A, Daoulas M, Clavel J, Le Guyader-Peyrou S, Monnereau A, Trétarre B, Colonna M, Cowppli-Bony A, Molinié F, Bara S, Degré D, Ganry O, Lapôtre-Ledoux B, Grosclaude P, Estève J, Bray F, Piñeros M, Sassi F, Stabenow R, Eberle A, Erb C, Nennecke A, Kieschke J, Sirri E, Kajueter H, Emrich K, Zeissig S, Holleczek B, Eisemann N, Katalinic A, Brenner H, Asquez R, Kumar V, Ólafsdóttir E, Tryggvadóttir L, Comber H, Walsh P, Sundseth H, Devigili E, Mazzoleni G, Giacomin A, Bella F, Castaing M, Sutera A, Gola G, Ferretti S, Serraino D, Zucchetto A, Lillini R, Vercelli M, Busco S, Pannozzo F, Vitarelli S, Ricci P, Pascucci C, Autelitano M, Cirilli C, Federico M, Fusco M, Vitale M, Usala M, Cusimano R, Mazzucco W, Michiara M, Sgargi P, Maule M, Sacerdote C, Tumino R, Di Felice E, Vicentini M, Falcini F, Cremone L, Budroni M, Cesaraccio R, Contrino M, Tisano F, Fanetti A, Maspero S, Candela G, Scuderi T, Gentilini M, Piffer S, Rosso S, Sacchetto L, Caldarella A, La Rosa F, Stracci F, Contiero P, Tagliabue G, Dei Tos A, Zorzi M, Zanetti R, Baili P, Berrino F, Gatta G, Sant M, Capocaccia R, De Angelis R, Liepina E, Maurina A, Smailyte G, Agius D, Calleja N, Siesling S, Visser O, Larønningen S, Møller B, Dyzmann-Sroka A, Trojanowski M, Góźdż S, Mężyk R, Grądalska-Lampart M, Radziszewska A, Didkowska J, Wojciechowska U, Błaszczyk J, Kępska K, Bielska-Lasota M, Kwiatkowska K, Forjaz G, Rego R, Bastos J, Silva M, Antunes L, Bento M, Mayer-da-Silva A, Miranda A, Coza D, Todescu A, Valkov M, Adamcik J, Safaei Diba C, Primic-Žakelj M, Žagar T, Stare J, Almar E, Mateos A, Quirós J, Bidaurrazaga J, Larrañaga N, Díaz García J, Marcos A, Marcos-Gragera R, Vilardell Gil M, Molina E, Sánchez M, Franch Sureda P, Ramos Montserrat M, Chirlaque M, Navarro C, Ardanaz E, Moreno-Iribas C, Fernández-Delgado R, Peris-Bonet R, Galceran J, Khan S, Lambe M, Camey B, Bouchardy C, Usel M, Ess S, Herrmann C, Bulliard J, Maspoli-Conconi M, Frick H, Kuehni C, Schindler M, Bordoni A, Spitale A, Chiolero A, Konzelmann I, Dehler S, Matthes K, Rashbass J, Stiller C, Fitzpatrick D, Gavin A, Bannon F, Black R, Brewster D, Huws D, White C, Finan P, Allemani C, Bonaventure A, Carreira H, Coleman M, Di Carlo V, Harewood R, Liu K, Matz M, Montel L, Nikšić M, Rachet B, Sanz N, Spika D, Stephens R, Peake M, Chalker E, Newman L, Baker D, Soeberg M, Aitken J, Scott C, Stokes B, Venn A, Farrugia H, Giles G, Threlfall T, Currow D, You H, Hendrix J, Lewis C. Erratum to “The histology of ovarian cancer: Worldwide distribution and implications for international survival comparisons (CONCORD-2)” [Gynecol. Oncol. 144 (2017) 405–413]. Gynecol Oncol 2017; 147:726. [DOI: 10.1016/j.ygyno.2017.06.032] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
26
|
Minicozzi P, Innos K, Sánchez MJ, Trama A, Walsh PM, Marcos-Gragera R, Dimitrova N, Botta L, Visser O, Rossi S, Tavilla A, Sant M, Hackl M, Zielonke N, Van Eycken E, Henau K, Valerianova Z, Dimitrova N, Sekerija M, Dušek L, Zvolský M, Mägi M, Aareleid T, Malila N, Seppä K, Bouvier A, Faivre J, Bossard N, Uhry Z, Colonna M, Stabenow R, Luttmann S, Eberle A, Brenner H, Nennecke A, Engel J, Schubert-Fritschle G, Heidrich J, Holleczek B, Katalinic A, Clough-Gorr K, Mazzoleni G, Bulatko A, Buzzoni C, Giacomin A, Ferretti S, Barchielli A, Caldarella A, Gatta G, Sant M, Amash H, Amati C, Baili P, Berrino F, Bonfarnuzzo S, Botta L, Capocaccia R, Di Salvo F, Foschi R, Margutti C, Meneghini E, Minicozzi P, Trama A, Serraino D, Maso LD, De Angelis R, Caldora M, Carrani E, Francisci S, Knijn A, Mallone S, Pierannunzio D, Roazzi P, Rossi S, Santaquilani M, Tavilla A, Pannozzo F, Natali M, Filiberti R, Marani E, Autelitano M, Spagnoli G, Cirilli C, Fusco M, Vitale M, Traina A, Staiti R, Vitale F, Cusimano R, Michiara M, Tumino R, Falcini F, Caiazzo A, Maspero S, Fanetti A, Zanetti R, Rosso S, Rugge M, Tognazzo S, Pildava S, Smailyte G, Johannesen T, Rachtan J, Góźdź S, Mężyk R, Błaszczyk J, Kępska K, Bielska-Lasota M, Forjaz de Lacerda G, Bento M, Antunes L, Miranda A, Mayer-da-Silva A, Safaei Diba C, Primic-Zakelj M, Almar E, Mateos A, Lopez de Munain A, Larrañaga N, Torrella-Ramos A, Díaz García J, Jimenez-Chillaron R, Marcos-Gragera R, Vilardell L, Moreno-Iribas C, Ardanaz E, Lambe M, Mousavi M, Bouchardy C, Usel M, Ess S, Frick H, Lorez M, Ess S, Herrmann C, Bordoni A, Spitale A, Konzelmann I, Visser O, Damhuis R, Otter R, Coleman M, Allemani C, Rachet B, Rashbass J, Broggio J, Verne J, Gavin A, Fitzpatrick D, Huws D, White C. Quality analysis of population-based information on cancer stage at diagnosis across Europe, with presentation of stage-specific cancer survival estimates: A EUROCARE-5 study. Eur J Cancer 2017; 84:335-353. [DOI: 10.1016/j.ejca.2017.07.015] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2017] [Revised: 07/04/2017] [Accepted: 07/11/2017] [Indexed: 11/28/2022]
|
27
|
Gatta G, Peris-Bonet R, Visser O, Stiller C, Marcos-Gragera R, Sánchez MJ, Lacour B, Kaatsch P, Berrino F, Rutkowski S, Botta L, Hackl M, Zielonke N, Oberaigner W, Van Eycken E, Henau K, Valerianova Z, Dimitrova N, Sekerija M, Storm H, Engholm G, Mägi M, Aareleid T, Malila N, Seppä K, Faivre J, Bossard N, Uhry Z, Colonna M, Clavel J, Lacour B, Desandes E, Brenner H, Kaatsch P, Katalinic A, Garami M, Jakab Z, Comber H, Mazzoleni G, Bulatko A, Buzzoni C, Giacomin A, Sutera Sardo A, Mancuso P, Ferretti S, Barchielli A, Caldarella A, Gatta G, Sant M, Amash H, Amati C, Baili P, Berrino F, Bonfarnuzzo S, Botta L, Capocaccia R, Di Salvo F, Foschi R, Margutti C, Meneghini E, Minicozzi P, Trama A, Serraino D, Zucchetto A, De Angelis R, Caldora M, Carrani E, Francisci S, Mallone S, Pierannunzio D, Roazzi P, Rossi S, Santaquilani M, Tavilla A, Pannozzo F, Busco S, Filiberti R, Marani E, Ricci P, Pascucci C, Autelitano M, Spagnoli G, Cirilli C, Fusco M, Vitale M, Usala M, Vitale F, Ravazzolo B, Michiara M, Merletti F, Maule M, Tumino R, Mangone L, Di Felice E, Falcini F, Iannelli A, Sechi O, Cesaraccio R, Piffer S, Madeddu A, Tisano F, Maspero S, Fanetti A, Candela P, Scuderi T, Stracci F, Bianconi F, Tagliabue G, Contiero P, Rugge M, Guzzinati S, Pildava S, Smailyte G, Calleja N, Agius D, Johannesen T, Rachtan J, Góźdź S, Mężyk R, Błaszczyk J, Bębenek M, Bielska-Lasota M, Forjaz de Lacerda G, Bento M, Castro C, Miranda A, Mayer-da-Silva A, Safaei Diba C, Primic-Zakelj M, Errezola M, Bidaurrazaga J, Vicente Raneda M, Díaz García J, Marcos-Navarro A, Marcos-Gragera R, Izquierdo Font A, Sanchez M, Chang D, Navarro C, Chirlaque M, Moreno-Iribas C, Ardanaz E, Peris-Bonet R, Pardo Romaguera E, Galceran J, Carulla M, Lambe M, Mousavi M, Bouchardy C, Usel M, Ess S, Frick H, Lorez M, Herrmann C, Bordoni A, Spitale A, Konzelmann I, Visser O, Aarts M, Otter R, Coleman M, Allemani C, Rachet B, Verne J, Stiller C, Gavin A, Donnelly C, Brewster D. Geographical variability in survival of European children with central nervous system tumours. Eur J Cancer 2017; 82:137-148. [DOI: 10.1016/j.ejca.2017.05.028] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2017] [Revised: 05/11/2017] [Accepted: 05/16/2017] [Indexed: 11/28/2022]
|
28
|
Xhaard C, Dumas A, Souchard V, Ren Y, Borson-Chazot F, Sassolas G, Schvartz C, Colonna M, Lacour B, Wonoroff AS, Velten M, Clero E, Maillard S, Marrer E, Bailly L, Mariné Barjoan E, Schlumberger M, Orgiazzi J, Adjadj E, Rubino C, Bouville A, Drozdovitch V, de Vathaire F. Are dietary reports in a case-control study on thyroid cancer biased by risk perception of Chernobyl fallout? Rev Epidemiol Sante Publique 2017; 65:301-308. [PMID: 28579185 DOI: 10.1016/j.respe.2017.02.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2016] [Revised: 02/07/2017] [Accepted: 02/13/2017] [Indexed: 10/19/2022] Open
Abstract
BACKGROUND In retrospective case-control studies performed following nuclear tests or nuclear accidents, individual thyroid radiation dose reconstructions are based on fallout and meteorological data from the residential area, demographic characteristics, and lifestyle as well as dietary information. Collecting the latter is a controversial step, as dietary declarations may be affected by the subjects' beliefs about their risk behavior. This report analyses the potential for such bias in a case-control study performed in eastern France. METHODS The study included 765 cases of differentiated thyroid carcinoma matched with 831 controls. Risk perceptions and beliefs of cases and controls were compared using Chi2 tests and differences in dietary reports were analyzed using a two-way ANOVA. RESULTS In general, atmospheric pollution and living near a nuclear power plant were the two major risks that may influence thyroid cancer occurrence cited by cases and controls. When focusing in particular on the consequences of the Chernobyl accident, cases were more likely to think that the consequences were responsible for thyroid cancer occurrence than controls. Vegetable consumption during the two months after the Chernobyl accident was correlated with the status of subjects, but not to their beliefs. Conversely, consumption of fresh dairy products was not correlated with the status or beliefs of subjects. CONCLUSION We found no evidence of systematic bias in dietary reports according to the status or beliefs held by subjects about the link between thyroid cancer occurrence and Chernobyl fallout. As such, these dietary reports may be used in further studies involving individual dosimetric reconstructions.
Collapse
Affiliation(s)
- C Xhaard
- Centre d'épidémiologie et de santé des populations (Cesp), U1018, epidemiology radiation group, Institut national de la santé et de la recherche médicale (Inserm), 94800 Villejuif, France; Gustave-Roussy, 94800 Villejuif, France; Université Paris-Saclay, 94800 Villejuif, France
| | - A Dumas
- Centre d'épidémiologie et de santé des populations (Cesp), U1018, epidemiology radiation group, Institut national de la santé et de la recherche médicale (Inserm), 94800 Villejuif, France; Gustave-Roussy, 94800 Villejuif, France; Université Paris-Saclay, 94800 Villejuif, France
| | - V Souchard
- Centre d'épidémiologie et de santé des populations (Cesp), U1018, epidemiology radiation group, Institut national de la santé et de la recherche médicale (Inserm), 94800 Villejuif, France; Gustave-Roussy, 94800 Villejuif, France; Université Paris-Saclay, 94800 Villejuif, France
| | - Y Ren
- Centre d'épidémiologie et de santé des populations (Cesp), U1018, epidemiology radiation group, Institut national de la santé et de la recherche médicale (Inserm), 94800 Villejuif, France; Gustave-Roussy, 94800 Villejuif, France; Université Paris-Saclay, 94800 Villejuif, France
| | - F Borson-Chazot
- Fédération d'endocrinologie, hospices civils de Lyon, groupement hospitalier Lyon-Est, 69677 Bron, France; Rhône-Alpes thyroid cancer registry, cancer research center of Lyon (UMR Inserm 1052, CNRS 5286), RTH Laennec faculty of medicine, university of Lyon, 69008 Lyon, France
| | - G Sassolas
- Rhône-Alpes thyroid cancer registry, cancer research center of Lyon (UMR Inserm 1052, CNRS 5286), RTH Laennec faculty of medicine, university of Lyon, 69008 Lyon, France
| | - C Schvartz
- Thyroid cancer registry of Champagne-Ardennes, institut Jean-Godinot, 51100 Reims, France
| | - M Colonna
- Cancer registry of Isère, 38240 Meylan, France
| | - B Lacour
- French national registry of childhood solid tumours, CHU de Nancy, 54505 Vandœuvre, France; Inserm UMRS1018, CESP, 94800 Villejuif, France
| | - A S Wonoroff
- Cancer registry of doubs, EA 3181, university hospital Besançon, 25030 Besançon, France
| | - M Velten
- Cancer Registry of Bas-Rhin, EA 3430, faculty of medicine, university of Strasbourg, 67085 Strasbourg, France
| | - E Clero
- Centre d'épidémiologie et de santé des populations (Cesp), U1018, epidemiology radiation group, Institut national de la santé et de la recherche médicale (Inserm), 94800 Villejuif, France; Gustave-Roussy, 94800 Villejuif, France; Université Paris-Saclay, 94800 Villejuif, France
| | - S Maillard
- Centre d'épidémiologie et de santé des populations (Cesp), U1018, epidemiology radiation group, Institut national de la santé et de la recherche médicale (Inserm), 94800 Villejuif, France; Gustave-Roussy, 94800 Villejuif, France; Université Paris-Saclay, 94800 Villejuif, France
| | - E Marrer
- Cancer registry of Haut-Rhin, Mulhouse hospital, 68051 Mulhouse, France
| | - L Bailly
- Public health department, university hospital Nice, 06202 Nice, France
| | - E Mariné Barjoan
- Public health department, university hospital Nice, 06202 Nice, France
| | | | - J Orgiazzi
- Department of endocrinology, Hospices civils de Lyon, 69310 Lyon, France
| | - E Adjadj
- Centre d'épidémiologie et de santé des populations (Cesp), U1018, epidemiology radiation group, Institut national de la santé et de la recherche médicale (Inserm), 94800 Villejuif, France; Université Paris-Saclay, 94800 Villejuif, France
| | - C Rubino
- Centre d'épidémiologie et de santé des populations (Cesp), U1018, epidemiology radiation group, Institut national de la santé et de la recherche médicale (Inserm), 94800 Villejuif, France; Gustave-Roussy, 94800 Villejuif, France; Université Paris-Saclay, 94800 Villejuif, France
| | - A Bouville
- Radiation epidemiology branch, division of cancer epidemiology and genetics, national cancer institute, Bethesda, USA
| | - V Drozdovitch
- Radiation epidemiology branch, division of cancer epidemiology and genetics, national cancer institute, Bethesda, USA
| | - F de Vathaire
- Centre d'épidémiologie et de santé des populations (Cesp), U1018, epidemiology radiation group, Institut national de la santé et de la recherche médicale (Inserm), 94800 Villejuif, France; Gustave-Roussy, 94800 Villejuif, France; Université Paris-Saclay, 94800 Villejuif, France.
| |
Collapse
|
29
|
Moradi Tuchayi S, Cunningham T, Ngo K, Raissi T, Ghebreselassie A, Eliane J, Shaffer A, Colonna M, Demehri S. 294 IL-33 mediates the development of the tumor-promoting immune environment in chronic inflammation. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.02.310] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
30
|
Dal Maso L, Tavilla A, Pacini F, Serraino D, van Dijk BAC, Chirlaque MD, Capocaccia R, Larrañaga N, Colonna M, Agius D, Ardanaz E, Rubió-Casadevall J, Kowalska A, Virdone S, Mallone S, Amash H, De Angelis R. Survival of 86,690 patients with thyroid cancer: A population-based study in 29 European countries from EUROCARE-5. Eur J Cancer 2017; 77:140-152. [PMID: 28410490 DOI: 10.1016/j.ejca.2017.02.023] [Citation(s) in RCA: 60] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2016] [Revised: 02/17/2017] [Accepted: 02/20/2017] [Indexed: 02/08/2023]
Abstract
BACKGROUND Incidence rates of thyroid cancer (TC) increased in several countries during the last 30 years, while mortality rates remained unchanged, raising important questions for treatment and follow-up of TC patients. This study updates population-based estimates of relative survival (RS) after TC diagnosis in Europe by sex, country, age, period and histology. METHODS Data from 87 cancer registries in 29 countries were extracted from the EUROCARE-5 dataset. One- and 5-year RS were estimated using the cohort approach for 86,690 adult TC patients diagnosed in 2000-2007 and followed-up to 12/31/2008. RS trends in 1999-2007 and 10-year RS in 2005-2007 were estimated using the period approach. RESULTS In Europe 2000-2007, 5-year RS after TC was 88% in women and 81% in men. Survival rates varied by country and were strongly correlated (Pearson ρ = 75%) with country-specific incidence rates. Five-year RS decreased with age (in women from >95% at age 15-54 to 57% at age 75+), from 98% in women and 94% in men with papillary TC to 14% in women and 12% in men with anaplastic TC. Proportion of papillary TC varied by country and increased over time, while survival rates were similar across areas and periods. In 1999-2007, 5-year RS increased by five percentage points for all TCs but only by two for papillary and by four for follicular TC. Ten-year RS in 2005-2007 was 89% in women and 79% in men. CONCLUSIONS The reported increasing TC survival trend and differences by area are mainly explained by the varying histological case-mix of cases.
Collapse
Affiliation(s)
- L Dal Maso
- Cancer Epidemiology Unit, CRO Aviano National Cancer Institute IRCCS, Aviano, Italy.
| | - A Tavilla
- Centro Nazionale di Epidemiologia, Sorveglianza e Promozione della Salute (CNESPS), Istituto Superiore di Sanità (ISS), Rome, Italy
| | - F Pacini
- Section of Endocrinology and Metabolism, Department of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy
| | - D Serraino
- Cancer Epidemiology Unit, CRO Aviano National Cancer Institute IRCCS, Aviano, Italy
| | - B A C van Dijk
- Netherlands Comprehensive Cancer Organisation (IKNL), Department of Research, Utrecht, The Netherlands; University of Groningen, University Medical Center Groningen, Department of Epidemiology, Groningen, The Netherlands
| | - M D Chirlaque
- Department of Epidemiology, Regional Health Council, IMIB-Arrixaca, Murcia, Spain; Department of Health and Social Sciences, Universidad de Murcia, Murcia, Spain; CIBER Epidemiology and Public Health CIBERESP, Madrid, Spain
| | - R Capocaccia
- Evaluative Epidemiology Unit, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - N Larrañaga
- CIBER Epidemiology and Public Health CIBERESP, Madrid, Spain; Basque Cancer Registry, Public Health Division of Gipuzkoa, Basque Health Department, Spain
| | - M Colonna
- Isere Cancer Registry (Grenoble), France; Francim Network (Toulouse), France
| | - D Agius
- Malta National Cancer Registry, Lecturer Public Health and Family Medicine, University of Malta, Malta
| | - E Ardanaz
- CIBER Epidemiology and Public Health CIBERESP, Madrid, Spain; Navarra Public Health Institute, Pamplona, Spain; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain
| | - J Rubió-Casadevall
- Medical Oncology Department, Epidemiology Unit and Girona Cancer Registry, Catalan Institute of Oncology, Girona, Spain
| | - A Kowalska
- Department of Endocrinology, Holycross Cancer Centre, Kielce, Poland
| | - S Virdone
- Cancer Epidemiology Unit, CRO Aviano National Cancer Institute IRCCS, Aviano, Italy
| | - S Mallone
- Centro Nazionale di Epidemiologia, Sorveglianza e Promozione della Salute (CNESPS), Istituto Superiore di Sanità (ISS), Rome, Italy
| | - H Amash
- Analytical Epidemiology and Health Impact Unit, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - R De Angelis
- Centro Nazionale di Epidemiologia, Sorveglianza e Promozione della Salute (CNESPS), Istituto Superiore di Sanità (ISS), Rome, Italy
| | | |
Collapse
|
31
|
Leber L, Tretarre B, Guizard AV, Colonna M, Grosclaude P, Bara S, Lapotre-Ledoux B, Troussard X, Woronoff AS, Bouvier V, Molinie F, Ligier K, Klein D, Velten M, Jégu J. Tendance du risque de second cancer lié au tabac en France entre 1989 et 2010. Rev Epidemiol Sante Publique 2017. [DOI: 10.1016/j.respe.2016.12.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
32
|
Colonna M, Acquasanta F, Gioia C, Celli A. Effect of telechelic ionic groups on the dispersion of organically modified clays in bisphenol A polycarbonate nanocomposites by in-situ polymerization using activated carbonates. EXPRESS POLYM LETT 2017. [DOI: 10.3144/expresspolymlett.2017.38] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
33
|
De Filippo E, Russotto P, Acosta L, Adamczyk M, Al-Ajlan A, Al-Garawi M, Al-Homaidhi S, Amorini F, Auditore L, Aumann T, Ayyad Y, Basrak Z, Benlliure J, Boisjoli M, Boretzky K, Brzychczyk J, Budzanowski A, Caesar C, Cardella G, Cammarata P, Chajecki Z, Chartier M, Chbihi A, Colonna M, Cozma M, Czech B, Di Toro M, Famiano M, Gannon S, Gašparić I, Grassi L, Guazzoni C, Guazzoni P, Heil M, Heilborn L, Introzzi R, Isobe T, Kezzar K, Kiš M, Krasznahorkay A, Kupny S, Kurz N, La Guidara E, Lanzalone G, Lasko P, Le Fèvre A, Leifels Y, Lemmon R, Li Q, Lombardo I, Łukasik J, Lynch W, Marini P, Matthews Z, May L, Minniti T, Mostazo M, Pagano A, Pagano E, Papa M, Pawłowski P, Pirrone S, Politi G, Porto F, Reviol W, Riccio F, Rizzo F, Rosato E, Rossi D, Santoro S, Sarantites D, Simon H, Skwirczynska I, Sosin Z, Stuhl L, Trautmann W, Trifirò A, Trimarchi M, Tsang M, Verde G, Veselsky M, Vigilante M, Wang Y, Wieloch A, Wigg P, Winkelbauer J, Wolter H, Wu P, Yennello S, Zambon P, Zetta L, Zoric M. The symmetry energy at suprasaturation density and the ASY-EOS experiment at GSI. EPJ Web Conf 2017. [DOI: 10.1051/epjconf/201713709002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
34
|
Parascandolo C, Pierroutsakou D, Alba R, Del Zoppo A, Maiolino C, Santonocito D, Agodi C, Baran V, Boiano A, Colonna M, Coniglione R, De Filippo E, Di Toro M, Emanuele U, Farinon F, Guglielmetti A, La Commara M, Martin B, Mazzocchi C, Mazzocco M, Rizzo C, Romoli M, Signorini C, Silvestri R, Soramel F, Strano E, Torresi D, Trifirò A, Trimarchi M. Dynamical Dipole mode in heavy-ion fusion reactions. EPJ Web Conf 2017. [DOI: 10.1051/epjconf/201716300043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
35
|
Fabris D, Gramegna F, Cicerchia M, Marchi T, Barlini S, Piantelli S, Bini M, Bruno M, Casini G, Cinausero M, D’Agostino M, Degerlier M, Gelli N, Mantovani G, Morelli L, Mabiala J, Olmi A, Pasquali G, Poggi G, Valdré S, Vardaci E, Fotina O, Kravchuk V, Colonna M, Ono A. Pre-equilibrium emission to study clustering in nuclei. EPJ Web Conf 2017. [DOI: 10.1051/epjconf/201716300016] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
36
|
Abstract
Innate lymphoid cells (ILCs) are a new class of immune cells that include natural killer (NK) cells and appear to be the innate counterparts to CD4(+) helper T cells and CD8(+) cytotoxic T cells based on developmental and functional similarities. Like T cells, both NK cells and other ILCs also show connections to the major histocompatibility complex (MHC). In human and mouse, NK cells recognize and respond to classical and nonclassical MHC I molecules as well as structural homologues, whereas mouse ILCs have recently been shown to express MHC II. We describe the history of MHC I recognition by NK cells and discuss emerging roles for MHC II expression by ILC subsets, making comparisons between both mouse and human when possible.
Collapse
Affiliation(s)
- M L Robinette
- Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO, USA
| | - M Colonna
- Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO, USA
| |
Collapse
|
37
|
|
38
|
Arnoult AC, Pernod G, Genty C, Galanaud JP, Colonna M, Sevestre MA, Bosson JL. Low incidence of cancer after venous thromboembolism: An update from the French OPTIMEV Cohort. ACTA ACUST UNITED AC 2016; 41:169-75. [PMID: 27080824 DOI: 10.1016/j.jmv.2016.03.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2015] [Accepted: 02/22/2016] [Indexed: 11/29/2022]
Abstract
BACKGROUND Recent studies have shown lower rates of cancer following venous thromboembolism (VTE) than previously described. OBJECTIVES To reassess the risk of cancer in patients with clinical symptoms of VTE with or without confirmed VTE. PATIENTS We used data from OPTIMEV, a French prospective multicenter observational study of patients presenting to hospital and community vascular medicine specialists with suspected VTE. Patients with confirmed VTE (1565) and matched controls without VTE (1847) were followed for 3 years (2006-2009). The main outcome was occurrence of cancer at 3 years, and death was a censoring event. RESULTS A total of 5.0% [4.0-6.3] of patients with VTE and 3.8% [3.0-4.9] without VTE developed cancer during follow-up. The adjusted hazard ratio (HR) was 1.2 [0.9-1.8] for patients with confirmed VTE (P=0.22). The overall standardized incidence ratio (SIR) was 1.4 [1.1-1.6] for our population, VTE+ and VTE-, compared with the general population, statistically significant (P<0.05). CONCLUSIONS We found a lower occurrence of cancer after VTE than previously described, with no significant difference between patients whether VTE was confirmed or not. Our results (low incidence and no difference between patients VTE+ or VTE-) provide no argument in favor of an extensive screening for cancer in case of VTE.
Collapse
Affiliation(s)
- A-C Arnoult
- Grenoble Alpes University, TIMC-IMAG, UMR 5525, 38043 Grenoble, France; Geneva University Hospital, Division of Angiology and Hemostasis, CH-1211 Geneva 14, Switzerland
| | - G Pernod
- Grenoble Alpes University, TIMC-IMAG, UMR 5525, 38043 Grenoble, France; Grenoble University Hospital, Department of Vascular Medicine, 38043 Grenoble, France
| | - C Genty
- Grenoble Alpes University, TIMC-IMAG, UMR 5525, 38043 Grenoble, France; Grenoble University Hospital, Clinical Research Center, 38043 Grenoble, France
| | - J-P Galanaud
- Montpellier University Hospital, Clinical Research Center, Department of Internal Medicine, 34090 Montpellier, France
| | - M Colonna
- Grenoble University Hospital, Isère Cancer Registry, 38043 Grenoble, France
| | - M-A Sevestre
- Grenoble Alpes University, TIMC-IMAG, UMR 5525, 38043 Grenoble, France; Amiens University Hospital, Department of Vascular Medicine, 80000 Amiens, France
| | - J-L Bosson
- Grenoble Alpes University, TIMC-IMAG, UMR 5525, 38043 Grenoble, France; Grenoble University Hospital, Clinical Research Center, 38043 Grenoble, France.
| |
Collapse
|
39
|
De Filippo E, Pagano A, Russotto P, Acosta L, Auditore L, Baran V, Cap T, Cardella G, Colonna M, Francalanza L, Gnoffo B, Lanzalone G, Lombardo I, Marquínez-Durán G, Maiolino C, Minniti T, Norella S, Pagano E, Papa M, Piasecki E, Pirrone S, Politi G, Porto F, Quattrocchi L, Rizzo F, Rosato E, Trifirò A, Trimarchi M, Verde G, Vigilante M, Siwek-Wilczyńska K, Wilczyński J. Sensitivity of N/Z ratio in projectile break-up of isobaric systems. EPJ Web of Conferences 2016. [DOI: 10.1051/epjconf/201611707017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
40
|
Cappuzzello F, Agodi C, Balestra F, Bijker R, Bonanno D, Bongiovanni D, Branchina V, Calabrese S, Calabretta L, Calanna A, Calvo D, Carbone D, Cavallaro M, Colonna M, Ferrero S, Foti A, Finocchiaro P, Giraudo G, Greco V, Iazzi F, Introzzi R, Lanzalone G, Lavagno A, Lo Presti D, Longhitano F, Muoio A, Pandola L, Rifuggiato D, Ruslan M, Santopinto E, Scaltrito L, Tudisco S, Zagatto V. The nuclear matrix elements of 0 νββdecay and the NUMEN project at INFN-LNS. EPJ Web of Conferences 2016. [DOI: 10.1051/epjconf/201611710003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
41
|
Gioia C, Banella MB, Marchese P, Vannini M, Colonna M, Celli A. Advances in the synthesis of bio-based aromatic polyesters: novel copolymers derived from vanillic acid and ε-caprolactone. Polym Chem 2016. [DOI: 10.1039/c6py00908e] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A new and sustainable pathway for the synthesis of polyesters and copolyesters derived from vanillic acid is reported. The one-pot procedure does not require either solvents or purification steps. New bio-based crystalline copolymers with tunable thermal properties are obtained.
Collapse
Affiliation(s)
- C. Gioia
- Department of Civil
- Chemical
- Environmental and Materials Engineering
- Alma Mater Studiorum
- University of Bologna
| | - M. B. Banella
- Department of Civil
- Chemical
- Environmental and Materials Engineering
- Alma Mater Studiorum
- University of Bologna
| | - P. Marchese
- Department of Civil
- Chemical
- Environmental and Materials Engineering
- Alma Mater Studiorum
- University of Bologna
| | - M. Vannini
- Department of Civil
- Chemical
- Environmental and Materials Engineering
- Alma Mater Studiorum
- University of Bologna
| | - M. Colonna
- Department of Civil
- Chemical
- Environmental and Materials Engineering
- Alma Mater Studiorum
- University of Bologna
| | - A. Celli
- Department of Civil
- Chemical
- Environmental and Materials Engineering
- Alma Mater Studiorum
- University of Bologna
| |
Collapse
|
42
|
Pirrone S, Politi G, Wieleczko J, De Filippo E, Gnoffo B, Russotto P, Trimarchi M, La Commara M, Vigilante M, Ademard G, Amorini F, Auditore L, Beck C, Berceanu I, Bonnet E, Borderie B, Cardella G, Chibihi A, Colonna M, D’Onofrio A, Frankland JD, Geraci E, Henry E, La Guidara E, Lanzalone G, Lautesse P, Lebhertz D, Le Neindre N, Lombardo I, Mazurek K, Norella S, Pagano A, Pagano E, Papa M, Piasecki E, Porto F, Quattrocchi L, Quinlann M, Rizzo F, Schroeder WU, Spadaccini G, Trifirò A, Toke J, Verde G. Isospin influence on the decay modes of compound systems produced in the 78,86Kr + 40,48Ca at 10 AMeV. EPJ Web of Conferences 2016. [DOI: 10.1051/epjconf/201612213001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
43
|
Russotto P, Chartier M, Cozma M, De Filippo E, Le Fèvre A, Gannon S, Gašparić I, Kiš M, Kupny S, Leifels Y, Lemmon R, Li Q, Łukasik J, Marini P, Pawłowski P, Trautmann W, Acosta L, Adamczyk M, Al-Ajlan A, Al-Garawi M, Al-Homaidhi S, Amorini F, Auditore L, Aumann T, Ayyad Y, Baran V, Basrak Z, Bassini R, Benlliure J, Boiano C, Boisjoli M, Boretzky K, Brzychczyk J, Budzanowski A, Cardella G, Cammarata P, Chajecki Z, Chbihi A, Colonna M, Czech B, Di Toro M, Famiano M, Greco V, Grassi L, Guazzoni C, Guazzoni P, Heil M, Heilborn L, Introzzi R, Isobe T, Kezzar K, Krasznahorkay A, Kurz N, La Guidara E, Lanzalone G, Lasko P, Lombardo I, Lynch W, Matthews Z, May L, Minniti T, Mostazo M, Pagano A, Papa M, Pirrone S, Pleskac R, Politi G, Porto F, Reifarth R, Reisdorf W, Riccio F, Rizzo F, Rosato E, Rossi D, Santoro S, Simon H, Skwirczynska I, Sosin Z, Stuhl L, Trifirò A, Trimarchi M, Tsang M, Verde G, Veselsky M, Vigilante M, Wieloch A, Wigg P, Wolter H, Wu P, Yennello S, Zambon P, Zetta L, Zoric M. The ASY-EOS Experiment at GSI. EPJ Web of Conferences 2016. [DOI: 10.1051/epjconf/201611707010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
44
|
Zheng H, Colonna M, Baran V, Burrello S. Effects of symmetry energy and momentum dependent interaction on low-energy reaction mechanisms. EPJ Web of Conferences 2016. [DOI: 10.1051/epjconf/201611707026] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
45
|
Burrello S, Aymard F, Colonna M, Gulminelli F, Raduta AR. Impact of pairing on thermodynamical properties of stellar matter. EPJ Web of Conferences 2016. [DOI: 10.1051/epjconf/201611707015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
46
|
Gnoffo B, Pirrone S, Politi G, La Commara M, Wieleczko J, De Filippo E, Russotto P, Trimarchi M, Vigilante M, Ademard G, Amorini F, Auditore L, Beck C, Bercenau I, Bonnet E, Borderie B, Cardella G, Chibihi A, Colonna M, D’Onofrio A, Frankland J, Geraci E, Henry E, La Guidara E, Lanzalone G, Lautesse P, Lebhertz D, LeNeidre N, Lombardo I, Mazurek K, Norella S, Pagano A, Pagano E, Papa M, Piasecki E, Porto F, Quattrocchi L, Quinlann M, Rizzo F, Shoroeder U, Spadaccini G, Trifirò A, Toke J, Verde G. Isospin influence on the decay modes of the systems produced in the 78,86Kr + 40,48Ca reactions at 10 AMeV. EPJ Web of Conferences 2016. [DOI: 10.1051/epjconf/201611708012] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
47
|
Parascandolo C, Pierroutsakou D, Alba R, Del Zoppo A, Maiolino C, Santonocito D, Agodi C, Baran V, Boiano A, Colonna M, Coniglione R, De Filippo E, Di Toro M, Emanuele U, Farinon F, Guglielmetti A, La Commara M, Martin B, Mazzocchi C, Mazzocco M, Rizzo C, Romoli M, Signorini C, Silvestri R, Soramel F, Strano E, Torresi D, Trifirò A, Trimarchi M. Dynamical Dipole mode in the 40,48Ca + 152,144Sm fusion reactions at 11 MeV/nucleon. EPJ Web of Conferences 2016. [DOI: 10.1051/epjconf/201611708016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
48
|
Shao G, Tang Z, Di Toro M, Colonna M, Gao X, Gao N, Zhao Y. Entanglement interaction and the phase diagram of strongly interacting matter. Int J Clin Exp Med 2015. [DOI: 10.1103/physrevd.92.114027] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
49
|
Seigneurin A, Labarère J, Duffy SW, Colonna M. Overdiagnosis associated with breast cancer screening: A simulation study to compare lead-time adjustment methods. Cancer Epidemiol 2015; 39:1128-35. [PMID: 26341587 DOI: 10.1016/j.canep.2015.08.013] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2015] [Revised: 07/13/2015] [Accepted: 08/20/2015] [Indexed: 10/23/2022]
Abstract
OBJECTIVE Estimating overdiagnosis associated with breast cancer screening may use annual incidence rates of cancer. We simulated populations invited to screening programmes to assess two lead-time adjustment methods. METHODS Overdiagnosis estimates were computed using the compensatory drop method, which considered the decrease in incidence of cancers among older age groups no longer offered screening, and the method based on the decrease in incidence of late-stage cancers. RESULTS The true value of overdiagnosis was 0% in all the data sets simulated. The compensatory drop method yielded an overdiagnosis estimate of -0.1% (95% credibility interval -0.5% to 0.5%) when participation rates among the population and risk of cancers were constant. However, if participation rates increased with calendar year as well as risk of cancer with birth cohorts, the overdiagnosis estimated was 11.0% (10.5-11.6%). Using the method based on the incidence of early- and late-stage cancers, overdiagnosis estimates were 8.9% (8.5-9.3%) and 17.6% (17.4-17.9%) when participation rates and risks of cancer were constant or increased with time, respectively. CONCLUSION Adjustment for lead time based on the compensatory drop method is accurate only when participation rates and risks of cancer remain constant, whereas the adjustment method based on the incidence of early- and late-stage cancers results in overestimating overdiagnosis regardless of stability of participation rates and breast cancer risk.
Collapse
Affiliation(s)
- A Seigneurin
- Unité d'évaluation médicale, Pavillon Taillefer, Centre Hospitalier Universitaire de Grenoble, Cs 10217, 38043 Grenoble Cedex 9, France; Université Joseph Fourier Grenoble 1, Techniques de l'Ingénierie Médicale et de la Complexité - Informatique Mathématiques et Applications Grenoble, Unité Mixte de Recherche 5525, 38041 Grenoble, France.
| | - J Labarère
- Unité d'évaluation médicale, Pavillon Taillefer, Centre Hospitalier Universitaire de Grenoble, Cs 10217, 38043 Grenoble Cedex 9, France; Université Joseph Fourier Grenoble 1, Techniques de l'Ingénierie Médicale et de la Complexité - Informatique Mathématiques et Applications Grenoble, Unité Mixte de Recherche 5525, 38041 Grenoble, France
| | - S W Duffy
- Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, Charterhouse Square, London EC1 M 6BQ, UK
| | - M Colonna
- Registre du Cancer de l'Isère, Pavillon E, Centre Hospitalier Universitaire de Grenoble, Cs 10217, 38043 Grenoble Cedex 9, France
| |
Collapse
|
50
|
Marcos-Gragera R, Mallone S, Kiemeney LA, Vilardell L, Malats N, Allory Y, Sant M, Hackl M, Zielonke N, Oberaigner W, Van Eycken E, Henau K, Valerianova Z, Dimitrova N, Sekerija M, Zvolský M, Dušek L, Storm H, Engholm G, Mägi M, Aareleid T, Malila N, Seppä K, Velten M, Troussard X, Bouvier V, Launoy G, Guizard A, Faivre J, M. Bouvier A, Arveux P, Maynadié M, Woronoff A, Robaszkiewicz M, Baldi I, Monnereau A, Tretarre B, Bossard N, Belot A, Colonna M, Molinié F, Bara S, Schvartz C, Lapôtre-Ledoux B, Grosclaude P, Meyer M, Stabenow R, Luttmann S, Eberle A, Brenner H, Nennecke A, Engel J, Schubert-Fritschle G, Kieschke J, Heidrich J, Holleczek B, Katalinic A, Jónasson J, Tryggvadóttir L, Comber H, Mazzoleni G, Bulatko A, Buzzoni C, Giacomin A, Sutera Sardo A, Mazzei A, Ferretti S, Crocetti E, Manneschi G, Gatta G, Sant M, Amash H, Amati C, Baili P, Berrino F, Bonfarnuzzo S, Botta L, Di Salvo F, Foschi R, Margutti C, Meneghini E, Minicozzi P, Trama A, Serraino D, Zucchetto A, De Angelis R, Caldora M, Capocaccia R, Carrani E, Francisci S, Mallone S, Pierannunzio D, Roazzi P, Rossi S, Santaquilani M, Tavilla A, Pannozzo F, Busco S, Bonelli L, Vercelli M, Gennaro V, Ricci P, Autelitano M, Randi G, Ponz De Leon M, Marchesi C, Cirilli C, Fusco M, Vitale M, Usala M, Traina A, Zarcone M, Vitale F, Cusimano R, Michiara M, Tumino R, Giorgi Rossi P, Vicentini M, Falcini F, Iannelli A, Sechi O, Cesaraccio R, Piffer S, Madeddu A, Tisano F, Maspero S, Fanetti A, Zanetti R, Rosso S, Candela P, Scuderi T, Stracci F, Rocca A, Tagliabue G, Contiero P, Dei Tos A, Tognazzo S, Pildava S, Smailyte G, Calleja N, Micallef R, Johannesen T, Rachtan J, Gózdz S, Mezyk R, Blaszczyk J, Kepska K, Bielska-Lasota M, Forjaz de Lacerda G, Bento M, Antunes L, Miranda A, Mayer-da-Silva A, Nicula F, Coza D, Safaei Diba C, Primic-Zakelj M, Almar E, Mateos A, Errezola M, Larrañaga N, Torrella-Ramos A, Díaz García J, Marcos-Navarro A, Marcos-Gragera R, Vilardell L, Sanchez M, Molina E, Navarro C, Chirlaque M, Moreno-Iribas C, Ardanaz E, Galceran J, Carulla M, Lambe M, Khan S, Mousavi M, Bouchardy C, Usel M, Ess S, Frick H, Lorez M, Ess S, Herrmann C, Bordoni A, Spitale A, Konzelmann I, Visser O, Aben K, Coleman M, Allemani C, Rachet B, Verne J, Easey N, Lawrence G, Moran T, Rashbass J, Roche M, Wilkinson J, Gavin A, Fitzpatrick D, Brewster D, Huws D, White C, Otter R. Urinary tract cancer survival in Europe 1999–2007: Results of the population-based study EUROCARE-5. Eur J Cancer 2015; 51:2217-2230. [DOI: 10.1016/j.ejca.2015.07.028] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2015] [Revised: 07/02/2015] [Accepted: 07/20/2015] [Indexed: 12/22/2022]
|